Antibody molecules that bind to nkp30 and uses thereof

Abstract

To provide antibody molecules that specifically bind to NKp30, where the antibody molecules can be used to treat, prevent and / or diagnose cancerous, autoimmune or infectious conditions and disorders.SOLUTION: The present invention provides an isolated antibody molecule that binds to NKp30, comprising specific amino acid sequences in a heavy chain complementarity determining region and a light chain complementarity determining region, where the amino acid sequences may comprise a sequence with no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletion).SELECTED DRAWING: None

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Application No. 62 / 808,582, filed February 21, 2019, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on February 20, 2020, is named E2070-7025WO_SL.txt and is 517,567 bytes in size. [Background technology]

[0003] Natural killer (NK) cells recognize and destroy tumor and virus-infected cells in an antibody-independent manner. Regulation of NK cells is mediated by activating and inhibiting receptors on the NK cell surface. One family of activating receptors is the natural cytotoxicity receptors (NCRs), which include NKp30, NKp44, and NKp46.

[0004] Considering the importance of immune checkpoint pathways in controlling immune responses, there is a need to develop new agents that modulate the activity of immunosuppressive proteins, such as PD-1, thereby resulting in activation of the immune system. Such agents can be used, for example, in cancer immunotherapy, and in the treatment of other conditions, such as chronic infections. Summary of the Invention [Means for solving the problem]

[0005] Disclosed herein are antibody molecules (e.g., humanized antibody molecules) that bind to NKp30 with high affinity and specificity. Nucleic acid molecules encoding the antibody molecules, expression vectors, host cells, and methods for making the antibody molecules are also provided. Multispecific or bispecific or multifunctional antibody molecules and pharmaceutical compositions comprising the antibody molecules are also provided. The anti-NKp30 antibody molecules disclosed herein can be used (alone or in combination with other drugs or therapeutic modalities) to treat, prevent, and / or diagnose disorders such as cancerous disorders (e.g., solid tumors and soft tissue tumors), and autoimmune and infectious diseases. Thus, disclosed herein are compositions and methods for detecting NKp30, as well as methods for treating various disorders, including cancer, autoimmune and / or infectious diseases, using anti-NKp30 antibody molecules.

[0006] Accordingly, in one aspect, the invention features an antibody molecule (e.g., an isolated or recombinant antibody molecule) that includes one or more sequences according to the enumerated embodiments below. Further features of any of the disclosed antibody molecules, multifunctional molecules, nucleic acids, vectors, host cells, or methods include one or more of the enumerated embodiments below.

[0007] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following recited embodiments. [Brief description of the drawings]

[0008] [Figure 1] Figure 1 is a graph showing binding of NKp30 antibody to NK92 cells. Data was calculated as percent-AF747 positive population. [Diagram 2] 2 is a graph showing activation of NK92 cells by NKp30 antibodies. Data was generated using a hamster anti-NKp30 mAb. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Enumerated Embodiments 1. An isolated antibody molecule that binds to NKp30, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 7313 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 7315 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions); and / or (ii) an antibody molecule comprising a light chain variable region (VL) comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 7326 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), the VLCDR2 amino acid sequence of SEQ ID NO: 7327 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or the VLCDR3 amino acid sequence of SEQ ID NO: 7329 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

[0010] 2. The antigen-binding domain is (i) a VH comprising an amino acid sequence of any one of SEQ ID NOs: 7298 or 7300 to 7304 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 7298 or 7300 to 7304); and / or (ii) a VL comprising any one of the amino acid sequences of SEQ ID NOs: 7299 or 7305 to 7309 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 7299 or 7305 to 7309); The antibody molecule of embodiment 1, comprising:

[0011] 3. The antigen-binding domain comprises: (i)) a VH comprising the amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising the amino acid sequence of SEQ ID NO: 7305 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7305); or (ii) a VH comprising the amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising the amino acid sequence of SEQ ID NO: 7309 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7309). The antibody molecule of embodiment 2, comprising:

[0012] 4. The antigen-binding domain comprises: (i) the amino acid sequence of SEQ ID NO: 7310 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7310); or (ii) the amino acid sequence of SEQ ID NO: 7311 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7311); 4. The antibody molecule of any of embodiments 1 to 3, comprising:

[0013] 5. An isolated antibody molecule that binds to NKp30, (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6000 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and (ii) an antibody molecule comprising a light chain variable region (VL) comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6063 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), the VLCDR2 amino acid sequence of SEQ ID NO: 6064 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or the VLCDR3 amino acid sequence of SEQ ID NO: 7293 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

[0014] 6. The antigen-binding domain comprises: (i) a heavy chain variable region (VH) comprising the heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6000, the VHCDR2 amino acid sequence of SEQ ID NO: 6001, and / or the VHCDR3 amino acid sequence of SEQ ID NO: 6002; and (ii) a light chain variable region (VL) comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6063, the VLCDR2 amino acid sequence of SEQ ID NO: 6064, and / or the VLCDR3 amino acid sequence of SEQ ID NO: 7293 The antibody molecule of embodiment 5, comprising:

[0015] 7. The antigen-binding domain comprises: (1) a heavy chain variable region (VH) comprising a heavy chain variable region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6003 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR2 amino acid sequence of SEQ ID NO: 6004 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO: 6005 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VHFWR4 amino acid sequence of SEQ ID NO: 6006 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom); and / or (2) A light chain variable region (VL) comprising the amino acid sequence of light chain variable region 1 (VLFWR1) of SEQ ID NO: 6066 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), the amino acid sequence of VLFWR2 of SEQ ID NO: 6067 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), the amino acid sequence of VLFWR3 of SEQ ID NO: 7292 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), or the amino acid sequence of VLFWR4 of SEQ ID NO: 6069 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions). 7. The antibody molecule of embodiment 5 or 6, comprising:

[0016] 8. The antigen-binding domain comprises: (1) the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6003; a heavy chain variable region (VH) comprising the VHFWR2 amino acid sequence of SEQ ID NO:6004, the VHFWR3 amino acid sequence of SEQ ID NO:6005, or the VHFWR4 amino acid sequence of SEQ ID NO:6006; and (3) A light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6066, the VLFWR2 amino acid sequence of SEQ ID NO: 6067, the VLFWR3 amino acid sequence of SEQ ID NO: 7292, or the VLFWR4 amino acid sequence of SEQ ID NO: 6069 The antibody molecule of embodiment 7, comprising:

[0017] 9. The antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 6121 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6121); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 7294 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 7294). 9. The antibody molecule of any one of embodiments 5 to 8, comprising:

[0018] 10. The antibody molecule of any one of embodiments 5 to 9, wherein the antigen-binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 6148 or 6149 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6148 or 6149).

[0019] 11. The antibody molecule of any of embodiments 5 to 10, wherein the antigen-binding domain comprises a light chain comprising the amino acid sequence of SEQ ID NO: 6150 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6150).

[0020] 12. The antibody molecule of any of embodiments 5 to 11, wherein the antigen-binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 6148 or 6149 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6148 or 6149), and a light chain comprising the amino acid sequence of SEQ ID NO: 6150 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6150).

[0021] 13. The antibody molecule of any of embodiments 5 to 12, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6014 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6015 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6016 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6017 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0022] 14. The antibody molecule of embodiment 13, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6014, the VHFWR2 amino acid sequence of SEQ ID NO: 6015, the VHFWR3 amino acid sequence of SEQ ID NO: 6016, or the VHFWR4 amino acid sequence of SEQ ID NO: 6017.

[0023] 15. The antibody molecule of embodiment 14, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6123 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6123).

[0024] 16. The antibody molecule of any of embodiments 5 to 15, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6018 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6019 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6020 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6021 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0025] 17. The antibody molecule of embodiment 16, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6018, the VHFWR2 amino acid sequence of SEQ ID NO: 6019, the VHFWR3 amino acid sequence of SEQ ID NO: 6020, or the VHFWR4 amino acid sequence of SEQ ID NO: 6021.

[0026] 18. The antibody molecule of embodiment 17, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6124 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6124).

[0027] 19. The antibody molecule of any of embodiments 5 to 18, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6022 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6023 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6024 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6025 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0028] 20. The antibody molecule of embodiment 19, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6022, the VHFWR2 amino acid sequence of SEQ ID NO: 6023, the VHFWR3 amino acid sequence of SEQ ID NO: 6024, or the VHFWR4 amino acid sequence of SEQ ID NO: 6025.

[0029] 21. The antibody molecule of embodiment 20, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6125 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6125).

[0030] 22. The antigen-binding domain comprises a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6026 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR2 amino acid sequence of SEQ ID NO: 6027 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO: 6028 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions 22. The antibody molecule of any of embodiments 5 to 21, comprising a heavy chain variable region (VH) comprising the VHFWR4 amino acid sequence of SEQ ID NO: 6029 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0031] 23. The antibody molecule of embodiment 22, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6026, the VHFWR2 amino acid sequence of SEQ ID NO: 6027, the VHFWR3 amino acid sequence of SEQ ID NO: 6028, or the VHFWR4 amino acid sequence of SEQ ID NO: 6029.

[0032] 24. The antibody molecule of embodiment 23, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6126 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6126).

[0033] 25. The antibody molecule of any of embodiments 5 to 24, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6030 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6032 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6033 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6034 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0034] 26. The antibody molecule of embodiment 25, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6030, the VHFWR2 amino acid sequence of SEQ ID NO: 6032, the VHFWR3 amino acid sequence of SEQ ID NO: 6033, or the VHFWR4 amino acid sequence of SEQ ID NO: 6034.

[0035] 27. The antibody molecule of embodiment 26, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6127 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6127).

[0036] 28. The antibody molecule of any of embodiments 5 to 27, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6035 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6036 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6037 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6038 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0037] 29. The antibody molecule of embodiment 28, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6035, the VHFWR2 amino acid sequence of SEQ ID NO: 6036, the VHFWR3 amino acid sequence of SEQ ID NO: 6037, or the VHFWR4 amino acid sequence of SEQ ID NO: 6038.

[0038] 30. The antibody molecule of embodiment 29, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6128 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6128).

[0039] 31. The antibody molecule of any of embodiments 5, 6, or 13 to 30, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6077 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6078 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6079 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6080 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0040] 32. The antibody molecule of embodiment 31, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6077, the VLFWR2 amino acid sequence of SEQ ID NO: 6078, the VLFWR3 amino acid sequence of SEQ ID NO: 6079, or the VLFWR4 amino acid sequence of SEQ ID NO: 6080.

[0041] 33. The antibody molecule of embodiment 32, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6137 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6137).

[0042] 34. The antibody molecule of any of embodiments 5, 6, or 13 to 30, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6081 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6082 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6083 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6084 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0043] 35. The antibody molecule of embodiment 34, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6081, the VLFWR2 amino acid sequence of SEQ ID NO: 6082, the VLFWR3 amino acid sequence of SEQ ID NO: 6083, or the VLFWR4 amino acid sequence of SEQ ID NO: 6084.

[0044] 36. The antibody molecule of embodiment 35, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6138 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6138).

[0045] 37. The antigen-binding domain comprises a light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6085 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6086 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 6087 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions 31. The antibody molecule of any of embodiments 5, 6, or 13 to 30, comprising a light chain variable region (VL) comprising the VLFWR4 amino acid sequence of SEQ ID NO: 6088 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0046] 38. The antibody molecule of embodiment 37, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6085, the VLFWR2 amino acid sequence of SEQ ID NO: 6086, the VLFWR3 amino acid sequence of SEQ ID NO: 6087, or the VLFWR4 amino acid sequence of SEQ ID NO: 6088.

[0047] 39. The antibody molecule of embodiment 38, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6139 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6139).

[0048] 40. The antibody molecule of any of embodiments 5, 6, or 13 to 30, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6089 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6090 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6091 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6092 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0049] 41. The antibody molecule of embodiment 40, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6089, the VLFWR2 amino acid sequence of SEQ ID NO: 6090, the VLFWR3 amino acid sequence of SEQ ID NO: 6091, or the VLFWR4 amino acid sequence of SEQ ID NO: 6092.

[0050] 42. The antibody molecule of embodiment 41, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6140 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6140).

[0051] 43. The antibody molecule of any of embodiments 5, 6, or 13 to 30, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6093 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6094 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6095 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6096 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0052] 44. The antibody molecule of embodiment 43, wherein the antigen-binding domain comprises the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6093, the VLFWR2 amino acid sequence of SEQ ID NO: 6094, the VLFWR3 amino acid sequence of SEQ ID NO: 6095, or the VLFWR4 amino acid sequence of SEQ ID NO: 6096.

[0053] 45. The antibody molecule of embodiment 44, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6141 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6141).

[0054] 46. ​​An isolated antibody molecule that binds to NKp30, (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6007 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6008 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6009 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and (ii) an antibody molecule comprising a light chain variable region (VL) comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), the VLCDR2 amino acid sequence of SEQ ID NO: 6071 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or the VLCDR3 amino acid sequence of SEQ ID NO: 6072 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

[0055] 47. The antigen-binding domain comprises: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6007, a VHCDR2 amino acid sequence of SEQ ID NO: 6008, and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6009; and (ii) a light chain variable region (VL) comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070, the VLCDR2 amino acid sequence of SEQ ID NO: 6071, and / or the VLCDR3 amino acid sequence of SEQ ID NO: 6072 47. The antibody molecule of embodiment 46, comprising:

[0056] 48. The antigen-binding domain comprises: (1) a heavy chain variable region (VH) comprising a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6010 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6011 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6012 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), or a VHFWR4 amino acid sequence of SEQ ID NO: 6013 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), and / or (2) A light chain variable region (VL) comprising a light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6073 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6074 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 6075 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VLFWR4 amino acid sequence of SEQ ID NO: 6076 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom); 48. The antibody molecule of embodiment 46 or 47, comprising:

[0057] 49. The antigen-binding domain comprises: (1) a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6010, the VHFWR2 amino acid sequence of SEQ ID NO: 6011, the VHFWR3 amino acid sequence of SEQ ID NO: 6012, or the VHFWR4 amino acid sequence of SEQ ID NO: 6013; and (3) A light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6073, the VLFWR2 amino acid sequence of SEQ ID NO: 6074, the VLFWR3 amino acid sequence of SEQ ID NO: 6075, or the VLFWR4 amino acid sequence of SEQ ID NO: 6076 49. The antibody molecule of embodiment 48, comprising:

[0058] 50. The antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 6122 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6122); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 6136 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6136). 50. The antibody molecule of any one of embodiments 46 to 49, comprising:

[0059] 51. The antibody molecule of any of embodiments 46 to 50, wherein the antigen-binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 6151 or 6152 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6151 or 6152).

[0060] 52. The antibody molecule of any of embodiments 46 to 51, wherein the antigen-binding domain comprises a light chain comprising the amino acid sequence of SEQ ID NO: 6153 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6153).

[0061] 53. The antibody molecule of any of embodiments 46 to 51, wherein the antigen-binding domain comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 6151 or 6152 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6151 or 6152), and a light chain comprising the amino acid sequence of SEQ ID NO: 6153 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6153).

[0062] 54. The antibody molecule of embodiment 46 or 47, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6039 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6040 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6041 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6042 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0063] 55. The antigen-binding domain comprises the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6039, the VHFWR2 amino acid sequence of SEQ ID NO: 6040, the VHFWR3 amino acid sequence of SEQ ID NO: 6041, or the VHFWR4 amino acid sequence of SEQ ID NO: 6042. 55. The antibody molecule of embodiment 54, comprising a heavy chain variable region (VH) comprising

[0064] 56. The antibody molecule of embodiment 55, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6129 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6129).

[0065] 57. The antibody molecule of embodiment 46 or 47, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain variable region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6043 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6044 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6045 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6046 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0066] 58. The antibody molecule of embodiment 57, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6043, the VHFWR2 amino acid sequence of SEQ ID NO: 6044, the VHFWR3 amino acid sequence of SEQ ID NO: 6045, or the VHFWR4 amino acid sequence of SEQ ID NO: 6046.

[0067] 59. The antibody molecule of embodiment 58, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6130 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6130).

[0068] 60. The antibody molecule of embodiment 46 or 47, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6047 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6048 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6049 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6050 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0069] 61. The antibody molecule of embodiment 60, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6047, the VHFWR2 amino acid sequence of SEQ ID NO: 6048, the VHFWR3 amino acid sequence of SEQ ID NO: 6049, or the VHFWR4 amino acid sequence of SEQ ID NO: 6050.

[0070] 62. The antibody molecule of embodiment 61, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6131 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6131).

[0071] 63. The antigen-binding domain comprises the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6051 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR2 amino acid sequence of SEQ ID NO: 6052 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), , e.g., a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6053 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6054 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0072] 64. The antibody molecule of embodiment 63, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6051, the VHFWR2 amino acid sequence of SEQ ID NO: 6052, the VHFWR3 amino acid sequence of SEQ ID NO: 6053, or the VHFWR4 amino acid sequence of SEQ ID NO: 6054.

[0073] 65. The antibody molecule of embodiment 64, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6132 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6132).

[0074] 66. The antibody molecule of embodiment 46 or 47, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6055 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6056 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6057 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6058 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0075] 67. The antibody molecule of embodiment 66, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6055, the VHFWR2 amino acid sequence of SEQ ID NO: 6056, the VHFWR3 amino acid sequence of SEQ ID NO: 6057, or the VHFWR4 amino acid sequence of SEQ ID NO: 6058.

[0076] 68. The antibody molecule of embodiment 67, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6133 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6133).

[0077] 69. The antibody molecule of embodiment 46 or 47, wherein the antigen-binding domain comprises a heavy chain variable region (VH) comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6059 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6060 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6061 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VHFWR4 amino acid sequence of SEQ ID NO: 6062 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0078] 70. The antigen-binding domain comprises the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6059, the VHFWR2 amino acid sequence of SEQ ID NO: 6060, the VHFWR3 amino acid sequence of SEQ ID NO: 6061, or the VHFWR4 amino acid sequence of SEQ ID NO: 6062. 70. The antibody molecule of embodiment 69, comprising a heavy chain variable region (VH) comprising

[0079] 71. The antibody molecule of embodiment 70, wherein the antigen-binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO: 6134 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6134).

[0080] 72. The antibody molecule of any of embodiments 46, 47, or 54 to 71, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6097 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6098 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6099 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6100 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0081] 73. The antibody molecule of embodiment 72, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6097, the VLFWR2 amino acid sequence of SEQ ID NO: 6098, the VLFWR3 amino acid sequence of SEQ ID NO: 6099, or the VLFWR4 amino acid sequence of SEQ ID NO: 6100.

[0082] 74. The antibody molecule of embodiment 73, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6142 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6142).

[0083] 75. The antibody molecule of any of embodiments 46, 47, or 54 to 74, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6101 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6102 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6103 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6104 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0084] 76. The antibody molecule of embodiment 75, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6101, the VLFWR2 amino acid sequence of SEQ ID NO: 6102, the VLFWR3 amino acid sequence of SEQ ID NO: 6103, or the VLFWR4 amino acid sequence of SEQ ID NO: 6104.

[0085] 77. The antibody molecule of embodiment 76, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6143 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6143).

[0086] 78. The antigen-binding domain comprises a light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6105 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6106 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions therefrom), , e.g., a sequence having 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6107 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6108 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom).

[0087] 79. The antibody molecule of embodiment 78, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6105, the VLFWR2 amino acid sequence of SEQ ID NO: 6106, the VLFWR3 amino acid sequence of SEQ ID NO: 6107, or the VLFWR4 amino acid sequence of SEQ ID NO: 6108.

[0088] 80. The antibody molecule of embodiment 79, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6144 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6144).

[0089] 81. The antibody molecule of any of embodiments 46, 47, or 54 to 80, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6109 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6110 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6111 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6112 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0090] 82. The antibody molecule of embodiment 81, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6109, the VLFWR2 amino acid sequence of SEQ ID NO: 6110, the VLFWR3 amino acid sequence of SEQ ID NO: 6111, or the VLFWR4 amino acid sequence of SEQ ID NO: 6112.

[0091] 83. The antibody molecule of embodiment 78, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6145 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6145).

[0092] 84. The antibody molecule of any of embodiments 46, 47, or 54 to 83, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6113 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6114 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6115 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6116 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0093] 85. The antigen-binding domain comprises the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6113, the VLFWR2 amino acid sequence of SEQ ID NO: 6114, the VLFWR3 amino acid sequence of SEQ ID NO: 6115, or the VLFWR4 amino acid sequence of SEQ ID NO: 6116. The antibody molecule of embodiment 84, comprising a light chain variable region (VL) comprising

[0094] 86. The antibody molecule of embodiment 85, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6146 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6146).

[0095] 87. The antibody molecule of any of embodiments 46, 47, or 54 to 86, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6117 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR2 amino acid sequence of SEQ ID NO: 6118 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), the VLFWR3 amino acid sequence of SEQ ID NO: 6119 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), or the VLFWR4 amino acid sequence of SEQ ID NO: 6120 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom).

[0096] 88. The antibody molecule of embodiment 87, wherein the antigen-binding domain comprises a light chain variable region (VL) comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6117, the VLFWR2 amino acid sequence of SEQ ID NO: 6118, the VLFWR3 amino acid sequence of SEQ ID NO: 6119, or the VLFWR4 amino acid sequence of SEQ ID NO: 6120.

[0097] 89. The antibody molecule of embodiment 88, wherein the antigen-binding domain comprises a VL comprising the amino acid sequence of SEQ ID NO: 6147 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6147).

[0098] 90. The antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 6122 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6122); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 6136 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6136). The antibody molecule of any one of the preceding embodiments, comprising:

[0099] 91. A multispecific molecule comprising an antibody molecule of any of embodiments 1 to 90. 92.a. a tumor targeting moiety, e.g., as described herein; b. A cytokine molecule, e.g., as described herein; c. A T cell engager, e.g., as described herein; or d. A stromal-modifying moiety, e.g., as described herein. 92. The multispecific molecule of embodiment 91, further comprising one, two, three, four or more of:

[0100] 93. The multispecific molecule of embodiment 91, further comprising a binding specificity that binds to an antigen present on the surface of autoreactive T cells, e.g., autoreactive T cells associated with an inflammatory or autoimmune disorder.

[0101] 94. The multispecific molecule of embodiment 91, further comprising a binding specificity that binds to infected cells, e.g., virally or bacterially infected cells. 95. The antibody molecule or multispecific molecule of any of the preceding embodiments, which is a monospecific antibody molecule, a bispecific antibody molecule, or a trispecific antibody molecule.

[0102] 96. The antibody molecule or multispecific molecule of any of the preceding embodiments, which is a monovalent antibody molecule, a bivalent antibody molecule, or a trivalent antibody molecule. 97. The antibody molecule or multispecific molecule of any of the preceding embodiments which is a full length antibody (e.g. an antibody comprising at least one, and preferably two, complete heavy chains and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g. a Fab, F(ab')2, Fv, single chain Fv, single domain antibody, diabody (dAb), bivalent antibody, or bispecific antibody or fragment thereof, single domain variant thereof, or camelid antibody).

[0103] 98. The antibody molecule or multispecific molecule of any of the preceding embodiments, comprising a heavy chain constant region selected from IgG1, IgG2, IgG3, or IgG4, or a fragment thereof. 99. The antibody molecule or multispecific molecule of any of the preceding embodiments, comprising a light chain constant region chosen from a kappa or lambda light chain constant region, or a fragment thereof.

[0104] 100. The antibody molecule or multispecific molecule of any of the preceding embodiments, wherein the immunoglobulin chain constant region (e.g., Fc region) is altered, e.g., mutated, to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function.

[0105] 101. The antibody molecule or multispecific molecule of any of the preceding embodiments, wherein the interface of the first and second immunoglobulin chain constant regions (e.g., Fc regions) is altered, e.g., mutated, to increase or decrease dimerization, e.g., compared to an interface that is not engineered.

[0106] 102. The antibody molecule or multispecific molecule of embodiment 101, wherein dimerization of immunoglobulin chain constant regions (e.g., Fc regions) is enhanced by providing one or more of paired holes and protrusions ("knobs-in-holes"), electrostatic interactions, or chain exchange at the Fc interface of the first and second Fc regions, thereby forming, for example, a higher ratio of heteromultimers:homomultimers compared to an interface that is not engineered.

[0107] 103. The antibody molecule or multispecific molecule of embodiment 101 or 102, wherein the immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution at one or more of positions 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, for example, of the Fc region of human IgG1.

[0108] 104. The antibody molecule or multispecific molecule of embodiment 103, wherein the immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution selected from T366S, L368A, or Y407V (e.g., corresponding to a pore or hole), or T366W (e.g., corresponding to a protrusion or knob), or a combination thereof.

[0109] 105. Linkers, e.g., a linker between a targeting moiety and a cytokine molecule or stromal modifying moiety, a linker between an immune cell engager, a cytokine molecule or stromal modifying moiety, and an immune cell engager, a cytokine molecule or stromal modifying moiety and an immunoglobulin chain constant region (e.g., an Fc region), a linker between a targeting moiety and an immunoglobulin chain constant region, or an immune cell engager and 105. The antibody molecule or multispecific molecule of any of embodiments 1 to 104, further comprising a linker between one or more of the immunoglobulin chain constant regions.

[0110] 106. The linker may be a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, The antibody molecule or multispecific molecule of embodiment 105, wherein the linker is selected from a linker, a rigid linker, a helical linker, or a non-helical linker.

[0111] 107. The antibody molecule or multispecific molecule of embodiment 106, wherein the linker is a peptide linker. 108. The antibody molecule or multispecific molecule of embodiment 107, wherein the peptide linker comprises Gly and Ser.

[0112] 109. An isolated nucleic acid molecule comprising a nucleotide sequence encoding any of the antibody molecules or multispecific or multifunctional molecules described herein, or a nucleotide sequence substantially homologous thereto (e.g., at least 95% to 99.9% identical thereto).

[0113] 110. An isolated nucleic acid encoding an antibody molecule or multispecific molecule of any of embodiments 1 to 108. 111. A vector, e.g., an expression vector, comprising one or more of the nucleic acid molecules of any of embodiments 109 or 110.

[0114] 112. A host cell comprising the nucleic acid molecule or vector of embodiment 111. 113. A method for making, e.g. producing, an antibody molecule or multispecific or multifunctional molecule polypeptide of any of embodiments 1 to 108, comprising culturing a host cell of embodiment 112 under suitable conditions, e.g. conditions suitable for gene expression and / or homo- or heterodimerization.

[0115] 114. A pharmaceutical composition comprising the antibody molecule or multispecific or multifunctional molecule polypeptide of any of embodiments 1 to 108 and a pharma- ceutically acceptable carrier, excipient or stabilizer.

[0116] 115. A method of treating cancer, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide of the preceding embodiments, wherein the multispecific antibody is administered in an amount effective to treat the cancer.

[0117] 116. The antibody molecule or multispecific or multifunctional molecule polypeptide of any of the preceding embodiments for use in treating cancer. 117. The method of embodiment 115 or the use of embodiment 116, wherein the cancer is a solid tumor cancer or a metastatic lesion.

[0118] 118. The method of embodiment 117 or the use of embodiment 117, wherein the solid tumor cancer is one or more of pancreatic cancer (e.g., pancreatic adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g., small cell or non-small cell lung cancer), skin cancer, ovarian cancer, or liver cancer.

[0119] 119. The method of embodiment 115 or the use of embodiment 116, wherein the cancer is a blood cancer. 120. The method of any of embodiments 115 or 116-119 or the use of any of embodiments 116-119, further comprising the step of administering a second therapeutic treatment.

[0120] 121. The method of embodiment 120 or the use of embodiment 120, wherein the second therapeutic treatment comprises a therapeutic agent (e.g., a chemotherapeutic agent, a biological agent, a hormonal therapy), radiation, or surgery. 122. The method of embodiment 121 or the use of embodiment 121, wherein the therapeutic agent is selected from a chemotherapeutic agent or a biological agent.

[0121] 123. A method of treating an autoimmune or inflammatory disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide of any of the preceding embodiments, wherein the multispecific antibody is administered in an amount effective to treat the autoimmune or inflammatory disorder.

[0122] 124. The antibody molecule or multispecific or multifunctional molecule polypeptide of any of the preceding embodiments for use in treating an autoimmune or inflammatory disorder. 125. A method of treating an infectious disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide of any of the preceding embodiments, wherein the multispecific antibody is administered in an amount effective to treat the infectious disorder.

[0123] 126. The antibody molecule or multispecific or multifunctional molecule polypeptide of any of the preceding embodiments for use in treating an infectious disorder. definition Certain terms are defined below.

[0124] As used herein, the articles "a" and "an" refer to one or more, e.g., at least one, of the grammatical object of the article. The use of the terms "a" or "an" when used with the term "comprising" herein can mean "one," but is also consistent with the meaning of "one or more," "at least one," and "one or more than one."

[0125] As used herein, "about" and "approximately" generally refer to an acceptable degree of error for the quantity measured given the nature or precision of the measurement. Exemplary degrees of error are within 20 percent (%), typically within 10%, and more typically within 5% of a given range of values.

[0126] As used herein, the term "molecule," as used in, e.g., antibody molecules, cytokine molecules, receptor molecules, includes full-length naturally occurring molecules as well as variants, e.g., functional variants (e.g., truncations, fragments, mutations (e.g., substantially similar sequences) or derivatized forms thereof), so long as at least one function and / or activity of the unmodified (e.g., naturally occurring) molecule remains.

[0127] As used herein, an "antibody molecule" refers to a protein, e.g., an immunoglobulin chain or a fragment thereof, that contains at least one immunoglobulin variable domain sequence. Antibody molecules include antibodies (e.g., full-length antibodies) and antibody fragments. In certain embodiments, an antibody molecule includes an antigen-binding or functional fragment of a full-length antibody or a full-length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that occurs naturally or is formed by the recombinant process of normal immunoglobulin gene fragments. In embodiments, an antibody molecule refers to an immunologically active antigen-binding portion of an immunoglobulin molecule, e.g., an antibody fragment. An antibody fragment, e.g., a functional fragment, is a portion of an antibody, e.g., a Fab, Fab', F(ab')2, F(ab)2, a variable fragment (Fv), a domain antibody (dAb), or a single-chain variable fragment (scFv). A functional antibody fragment binds to the same antigen that is recognized by an intact (e.g., full-length) antibody. The term "antibody fragment" or "functional fragment" also includes isolated fragments consisting of the variable regions, such as an "Fv" fragment consisting of the variable regions of the heavy and light chains, or a recombinant single chain polypeptide molecule in which the variable regions of the light and heavy chains are linked by a peptide linker ("scFv protein"). In some embodiments, an antibody fragment does not include a portion of an antibody that does not have antigen binding activity, e.g., an Fc fragment or a single amino acid residue. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g. , dAbs (domain antibodies), single chain, Fab, Fab', and F(ab')2 fragments, and single chain variable fragments (scFv).

[0128] As used herein, "immunoglobulin variable domain sequence" refers to an amino acid sequence capable of forming the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally occurring variable domain. For example, the sequence may or may not include one, two or more N-terminal or C-terminal amino acids, or may include other modifications compatible with forming a protein structure.

[0129] In embodiments, the antibody molecule is monospecific, e.g., comprises binding specificity for a single epitope. In some embodiments, the antibody molecule is multispecific, e.g., it comprises multiple immunoglobulin variable domain sequences, a first immunoglobulin variable domain sequence has binding specificity for a first epitope, and a second immunoglobulin variable domain sequence has binding specificity for a second epitope. In some embodiments, the antibody molecule is a bispecific antibody molecule. A "bispecific antibody molecule," as used herein, refers to an antibody molecule that has specificity for more than one (e.g., 2, 3, 4, or more) epitope and / or antigen.

[0130] As used herein, "antigen" (Ag) refers to a molecule that can trigger an immune response, e.g., involving activation of certain immune cells and / or antibody production. Any macromolecule, including almost any protein or peptide, can be an antigen. Antigens can also be derived from genomic recombinants or DNA. For example, any DNA that includes a nucleotide sequence or partial nucleotide sequence that encodes a protein that can induce an immune response encodes an "antigen." In embodiments, an antigen need not be encoded only by the full-length nucleotide sequence of a gene, nor need an antigen be encoded by a gene at all. In embodiments, an antigen can be synthesized or derived from a biological sample, e.g., a tissue sample, a tumor sample, a cell, or a fluid, that has other biological components. As used herein, "tumor antigen" or synonymously "cancer antigen" includes any molecule present on or associated with a cancer, e.g., a cancer cell or tumor microenvironment that can trigger an immune response. As used herein, "immune cell antigen" includes any present on or associated with an immune cell that can trigger an immune response.

[0131] An "antigen-binding site" or "binding site" of an antibody molecule refers to the portion of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that is involved in antigen binding. In an embodiment, the antigen-binding site is formed by amino acid residues of the variable regions (V) of the heavy (H) and light (L) chains. Three highly branched stretches in the variable regions of the heavy and light chains, called hypervariable regions, are located between more conserved adjacent regions called "framework regions" (FR). FRs are amino acid sequences that are naturally found between and adjacent to the hypervariable regions in immunoglobulins. In an embodiment, in an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are positioned relative to each other in three-dimensional space to form an antigen-binding surface that is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are called "complementarity determining regions" or "CDRs". Framework regions and CDRs are defined and described, for example, in Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., USDepartment of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917. Each variable chain (e.g., variable heavy and variable light chains) typically consists of three CDRs and four FRs, arranged from amino terminus to carboxy terminus in the following amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0132] As used herein, "cancer" can encompass all types of oncogenic processes and / or cancerous growths. In embodiments, cancer includes primary tumors, as well as metastatic tissues, or malignantly transformed cells, tissues, or organs. In embodiments, cancer includes all histopathologies and stages of cancer, e.g., stages of invasiveness / severity. In embodiments, cancer includes recurrent and / or resistant cancers. The terms "cancer" and "tumor" can be used interchangeably. For example, both terms encompass solid tumors and liquid tumors. As used herein, the terms "cancer" or "tumor" include precancers, as well as malignant cancers and tumors.

[0133] As used herein, "immune cells" refers to any of a variety of cells that function in the immune system, e.g., defend against infection and foreign agents. In embodiments, the term includes white blood cells, e.g., neutrophils, eosinophils, basophils, lymphocytes, and monocytes. Innate white blood cells include phagocytes (e.g., macrophages, neutrophils, and dendritic cells), mast cells, eosinophils, basophils, and natural killer cells. Innate white blood cells identify and eliminate pathogens by attacking larger pathogens through contact or by engulfing and killing microorganisms, and are mediators of the activation of adaptive immune responses. Cells of the adaptive immune system are a specialized type of white blood cell called lymphocytes. B cells and T cells are important types of lymphocytes and are derived from hematopoietic stem cells in the bone marrow. B cells are involved in humoral immune responses, and T cells are involved in cellular immune responses. The term "immune cells" includes immune effector cells.

[0134] The term "immune effector cell" as used herein refers to a cell that is involved in an immune response, e.g., promoting an immune effector response. Examples of immune effector cells include, but are not limited to, T cells, e.g., alpha / beta T cells and gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T cells, and mast cells.

[0135] The term "effector function" or "effector response" refers to a specialized function of a cell. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including secretion of cytokines.

[0136] The compositions and methods of the present invention encompass polypeptides and nucleic acids having a specific sequence or a substantially identical or similar sequence thereto, for example, a sequence that is at least 80%, 85%, 90%, 95% identical or more identical to a specific sequence. In the context of amino acid sequences, the term "substantially identical" is used herein to refer to a first amino acid sequence that contains a sufficient or minimal number of amino acid residues that are i) identical to a second amino acid sequence, or ii) are conservative substitutions of aligned amino acid residues in a second amino acid sequence, such that the first and second amino acid sequences can have a common structural domain and / or a common functional activity. For example, an amino acid sequence that contains a common structural domain has at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, for example, a sequence provided herein.

[0137] In the context of nucleotide sequences, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient number or a minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having a common functional activity, or encode a common polypeptide structural domain or a common polypeptide functional activity. For example, a first nucleic acid sequence that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 17 %, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0138] The term "variant" refers to a polypeptide having substantially the same amino acid sequence as a reference amino acid sequence or encoded by a substantially identical nucleotide sequence. In some embodiments, the variant is a functional variant.

[0139] The term "functional variant" refers to a polypeptide having an amino acid sequence substantially identical to a reference amino acid sequence, or a polypeptide encoded by a substantially identical nucleotide sequence, which may have one or more activations of the reference amino acid sequence.

[0140] Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows. To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., for optimal alignment, gaps can be introduced into one or both of the first and second amino acid or nucleic acid sequences, and non-homologous sequences can be ignored for comparison purposes). In a preferred embodiment, the length of the reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. If a position of the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology").

[0141] The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, that need to be introduced for optimal alignment of the two sequences.

[0142] Comparison of sequences and determination of percent identity between two sequences can be accomplished using mathematical algorithms. In a preferred embodiment, percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm incorporated in the GAP program of the GCG software package (available at www.gcg.com) using either a Blossum62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4, and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, percent identity between two nucleotide sequences is determined using the GAP program of the GCG software package (available at www.gcg.com) using a NWSgapdna.CMP matrix, and a gap weight of 40, 50, 60, 70, or 80, and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and which should be used unless otherwise specified) is a Blossum62 scoring matrix, with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0143] The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) incorporated into the ALIGN program (version 2.0), using a PAM120 residue weighting table, a gap length penalty of 12 and a gap penalty of 4.

[0144] The nucleic acid and protein sequences described herein can be used as "query sequences" to perform searches against public databases, for example to identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed using the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed using the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) can be used. See www.ncbi.nlm.nih.gov.

[0145] It is understood that the molecules of the present invention may have additional conservative or non-essential amino acid substitutions which do not have a substantial effect on their function. The term "amino acid" is intended to include all molecules, whether natural or synthetic, that contain both amino and acid functionalities and can be included in naturally occurring amino acid polymers. Exemplary amino acids include naturally occurring amino acids; their analogs, derivatives and congeners; amino acid analogs with variant side chains; and all stereoisomers of any of the foregoing. As used herein, the term "amino acid" includes both D or L optical isomers and peptidomimetics.

[0146] A "conservative amino acid substitution" refers to an amino acid residue that is replaced with an amino acid residue that has a similar side chain. Families of amino acid residues that have similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0147] The terms "polypeptide", "peptide" and "protein" (when single chain) are used interchangeably herein and refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. Polypeptides can be isolated from natural sources, produced by recombinant techniques from eukaryotic or prokaryotic hosts, or can be the product of synthetic techniques.

[0148] The terms "nucleic acid", "nucleic acid sequence", "nucleotide sequence", or "polynucleotide sequence" and "polynucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can be either single-stranded or double-stranded, and if single-stranded, can be the coding strand or the non-coding (antisense) strand. Polynucleotides The nucleotide may include modified nucleotides such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may be further modified after polymerization, for example, by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semi-synthetic, or synthetic origin that does not occur in nature or is linked to another polynucleotide in a non-natural sequence.

[0149] The term "isolated" as used herein refers to a material that is removed from its original or natural environment (e.g., the natural environment when it occurs in nature). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but an identical polynucleotide or polypeptide that is separated by human intervention from some or all of the coexisting materials in the natural system is isolated. Such a polynucleotide may be part of a vector, and / or such a polynucleotide or polypeptide may be part of a composition, and such a vector or composition may still be isolated in that it is not part of the environment in which it is found in nature.

[0150] Various aspects of the invention are described in further detail below. Additional definitions are set forth throughout the specification. Natural Killer Cell Engager Natural killer (NK) cells recognize and destroy tumor and virus-infected cells in an antibody-independent manner. Regulation of NK cells is mediated by activating and inhibiting receptors on the NK cell surface. One family of activating receptors is the natural cytotoxicity receptors (NCRs), including NKp30, NKp44, and NKp46. NCRs initiate tumor targeting by recognition of heparan sulfate on cancer cells. NKG2D is a receptor that provides both stimulatory and costimulatory innate immune responses in activated killer (NK) cells, leading to cytotoxic activity. DNAM1 is a receptor involved in cell-cell adhesion, lymphocyte signaling, cytotoxicity, and lymphokine secretion mediated by cytotoxic T lymphocytes (CTLs) and NK cells. DAP10 (also known as HCST) is a transmembrane adaptor protein that associates with KLRK1 in lymphoid and myeloid cells to form the activating receptor KLRK1-HCST, which plays a major role in inducing cytotoxicity against target cells expressing cell surface ligands such as MHC class I chain-associated MICA and MICB, and U(optionally L1)6-binding protein (ULBP); the KLRK1-HCST receptor plays a role in immune surveillance against tumors and is required for tumor cell lysis; indeed, melanoma cells that do not express KLRK1 ligands escape immune surveillance mediated by NK cells. CD16 is a receptor for the Fc region of IgG, binding complexed or aggregated IgG, and also monomeric IgG, thereby mediating antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses such as phagocytosis.

[0151] The present disclosure provides, inter alia, antibody molecules, e.g., multispecific (e.g., bi-, tri-, tetraspecific) or multifunctional molecules, engineered to contain one or more NK cell engagers that mediate binding to and / or activation of NK cells. Thus, in some embodiments, the NK cell engager is selected from an antigen-binding domain or ligand that binds (e.g., activates) NKp30, NKp40, NKp44, NKp46, NKG2D, DNAM1, DAP10, CD16 (e.g., CD16a, CD16b, or both), CRTAM, CD27, PSGL1, CD96, CD100 (SEMA4D), NKp80, CD244 (also known as SLAMF4 or 2B4), SLAMF6, SLAMF7, KIR2DS2, KIR2DS4, KIR3DS1, KIR2DS3, KIR2DS5, KIR2DS1, CD94, NKG2C, NKG2E, or CD160.

[0152] In some embodiments, the NK cell engager is an antigen-binding domain that binds to NKp30 (e.g., NKp30 present, e.g., expressed or displayed, on the surface of an NK cell) and comprises any of the CDR amino acid sequences, framework region (FWR) amino acid sequences, or variable region amino acid sequences disclosed in Tables 7-10. In some embodiments, the NK cell engager is an antigen binding domain that binds to NKp30 (e.g., NKp30 present, e.g., expressed or displayed, on the surface of an NK cell) and includes any CDR amino acid sequence, framework region (FWR) amino acid sequence, or variable region amino acid sequence disclosed in U.S. Patent No. 6,979,546, U.S. Patent No. 9,447,185, PCT Application Publication No. 2015 / 121383A1, PCT Application Publication No. 2016 / 110468A1, PCT Application Publication No. 2004 / 056392A1, or U.S. Application Publication No. 20070231322A1, which sequences are incorporated herein by reference. In some embodiments, binding of the NK cell engager, e.g., an antigen binding domain that binds to NKp30, to the NK cell activates the NK cell. An antigen-binding domain that binds to NKp30 (e.g., NKp30 present, e.g., expressed or displayed, on the surface of an NK cell) can be said to target NKp30, the NK cell, or both.

[0153] In some embodiments, an antigen-binding domain that binds NKp30 comprises one or more CDRs (e.g., VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and / or VLCDR3) disclosed in Table 7, Table 18, or Table 8, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto. In some embodiments, an antigen-binding domain that binds NKp30 comprises one or more framework regions (e.g., VHFWR1, VHFWR2, VHFWR3, VHFWR4, VLFWR1, VLFWR2, VLFWR3, and / or VLFWR4) disclosed in Table 7, Table 18, or Table 8, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto. In some embodiments, an antigen-binding domain that binds NKp30 comprises a VH and / or VL disclosed in Table 9, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto. In some embodiments, any of the VH domains disclosed in Table 9 can be paired with any of the VL domains disclosed in Table 9 to form an antigen-binding domain that binds NKp30. In some embodiments, an antigen-binding domain that binds NKp30 comprises an amino acid sequence disclosed in Table 10, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.

[0154] In some embodiments, the antigen-binding domain that binds to NKp30 comprises a VH comprising heavy chain complementarity determining region 1 (VHCDR1), VHCDR2, and VHCDR3, and a VL comprising light chain complementarity determining region 1 (VLCDR1), VLCDR2, and VLCDR3.

[0155] In some embodiments, VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 6001, and 7315, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 6001, and 6002, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 6008, and 6009, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 7385, and 7386, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequence of SEQ ID NOs: 7313, 7318, and 6009, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).

[0156] In some embodiments, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 7326, 7327, and 7329, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 6063, 6064, and 7293, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 6070, 6071, and 6072, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 6070, 6064, and 7321, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto).

[0157] In some embodiments, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 6001, 7315, 7326, 7327, and 7329, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 6001, 6002, 6063, 6064, and 7293, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequence of SEQ ID NOs: 7313, 6008, 6009, 6070, 6071, and 6072, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequence of SEQ ID NOs: 7313, 7385, 7315, 6070, 6064, and 7321, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 7313, 7318, 6009, 6070, 6064, and 7321, respectively (or sequences having at least 85%, 90%, 95%, or 99% identity thereto).

[0158] In some embodiments, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7298 or 7300-7304 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and / or the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7299 or 7305-7309 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH and VL comprise the amino acid sequence of SEQ ID NOs: 7302 and 7305, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH and VL comprise the amino acid sequence of SEQ ID NOs: 7302 and 7309, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).

[0159] In some embodiments, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6121 or 6123-6128 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and / or the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7294 or 6137-6141 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6122 or 6129-6134 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and / or the VL comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6136 or 6142-6147 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH and VL comprise the amino acid sequence of SEQ ID NOs: 7295 and 7296, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH and VL comprise the amino acid sequence of SEQ ID NOs: 7297 and 7296, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the VH and VL comprise the amino acid sequence of SEQ ID NOs: 6122 and 6136, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).

[0160] In some embodiments, the antigen-binding domain that binds NKp30 comprises the amino acid sequence of SEQ ID NO: 7310 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the antigen-binding domain that binds NKp30 comprises the amino acid sequence of SEQ ID NO: 7311 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto). In some embodiments, the antigen-binding domain that binds NKp30 comprises the amino acid sequence of SEQ ID NO: 6187, 6188, 6189, or 6190 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).

[0161] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6000 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). In some embodiments, an NKp30 antigen-binding domain comprises a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 6000, a VHCDR2 amino acid sequence of SEQ ID NO: 6001, and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002.

[0162] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VL comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6063 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6064 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 7293 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). In some embodiments, the antigen-binding domain targeting NKp30 comprises a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 6063, a VLCDR2 amino acid sequence of SEQ ID NO: 6064, and a VLCDR3 amino acid sequence of SEQ ID NO: 7293.

[0163] In some embodiments, the antigen binding domain targeting NKp30 is SEQ ID NO: 600 and a VH comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 0 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VL comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO:6063 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO:6064 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO:7293 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). In some embodiments, the NKp30 antigen-binding domain comprises a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:6000, a VHCDR2 amino acid sequence of SEQ ID NO:6001, and / or a VHCDR3 amino acid sequence of SEQ ID NO:6002, and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:6063, a VLCDR2 amino acid sequence of SEQ ID NO:6064, and a VLCDR3 amino acid sequence of SEQ ID NO:7293.

[0164] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO:6007 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO:6008 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO:6009 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). In some embodiments, an NKp30 antigen-binding domain comprises a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:6007, a VHCDR2 amino acid sequence of SEQ ID NO:6008, and / or a VHCDR3 amino acid sequence of SEQ ID NO:6009.

[0165] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VL comprising the light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), the VLCDR2 amino acid sequence of SEQ ID NO: 6071 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or the VLCDR3 amino acid sequence of SEQ ID NO: 6072 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). In some embodiments, the antigen-binding domain targeting NKp30 comprises a VL comprising the VLCDR1 amino acid sequence of SEQ ID NO: 6070, the VLCDR2 amino acid sequence of SEQ ID NO: 6071, and the VLCDR3 amino acid sequence of SEQ ID NO: 6072.

[0166] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6007 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6008 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6009 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6071 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), In some embodiments, the NKp30 antigen-binding domain comprises a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:6007, a VHCDR2 amino acid sequence of SEQ ID NO:6008, and / or a VHCDR3 amino acid sequence of SEQ ID NO:6009, and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:6070, a VLCDR2 amino acid sequence of SEQ ID NO:6071, and a VLCDR3 amino acid sequence of SEQ ID NO:6072.

[0167] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6003, the VHFWR2 amino acid sequence of SEQ ID NO:6004, the VHFWR3 amino acid sequence of SEQ ID NO:6005, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6006.

[0168] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6066, the VLFWR2 amino acid sequence of SEQ ID NO: 6067, the VLFWR3 amino acid sequence of SEQ ID NO: 7292, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6069.

[0169] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6003, the VHFWR2 amino acid sequence of SEQ ID NO:6004, the VHFWR3 amino acid sequence of SEQ ID NO:6005, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6006, and a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6066, the VLFWR2 amino acid sequence of SEQ ID NO:6067, the VLFWR3 amino acid sequence of SEQ ID NO:7292, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6069.

[0170] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6003 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6004 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6005 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6006.

[0171] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6066 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6067 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 7292 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6069.

[0172] In some embodiments, the antigen-binding domain targeting NKp30 is selected from the group consisting of a VHFWR1 amino acid sequence of SEQ ID NO:6003 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR2 amino acid sequence of SEQ ID NO:6004 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO:6005 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR4 amino acid sequence of SEQ ID NO:6006 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR5 amino acid sequence of SEQ ID NO:6007 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR6 amino acid sequence of SEQ ID NO:6008 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR7 amino acid sequence of SEQ ID NO:6009 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or less mutations and a VL comprising a VLFWR1 amino acid sequence of SEQ ID NO: 6066 (or a sequence having no more than 1, 2, or 3 mutations, e.g., substitutions, additions, or deletions), a VLFWR2 amino acid sequence of SEQ ID NO: 6067 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), a VLFWR3 amino acid sequence of SEQ ID NO: 7292 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or a VLFWR4 amino acid sequence of SEQ ID NO: 6069.

[0173] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6010, the VHFWR2 amino acid sequence of SEQ ID NO:6011, the VHFWR3 amino acid sequence of SEQ ID NO:6012, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6013.

[0174] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6073, the VLFWR2 amino acid sequence of SEQ ID NO:6074, the VLFWR3 amino acid sequence of SEQ ID NO:6075, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6076.

[0175] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6010, the VHFWR2 amino acid sequence of SEQ ID NO:6011, the VHFWR3 amino acid sequence of SEQ ID NO:6012, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6013, and a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6073, the VLFWR2 amino acid sequence of SEQ ID NO:6074, the VLFWR3 amino acid sequence of SEQ ID NO:6075, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6076.

[0176] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6010 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6011 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6012 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6013.

[0177] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO:6073 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO:6074 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO:6075 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO:6076.

[0178] In some embodiments, the antigen-binding domain targeting NKp30 has the VHFWR1 amino acid sequence of SEQ ID NO: 6010 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6011 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6012 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or more mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR4 amino acid sequence of SEQ ID NO: 6013 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or more mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR5 amino acid sequence of SEQ ID NO: 6014 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or more mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR6 amino acid sequence of SEQ ID NO: 6015 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or more mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR7 amino acid sequence of SEQ ID NO: 6016 (or a sequence having 1, 2, 3, 4, 5, 6, and a VL comprising a VLFWR1 amino acid sequence of SEQ ID NO: 6073 (or a sequence having no more than one, two or three mutations, e.g., substitutions, additions or deletions), a VLFWR2 amino acid sequence of SEQ ID NO: 6074 (or a sequence having no more than one mutation, e.g., substitutions, additions or deletions), a VLFWR3 amino acid sequence of SEQ ID NO: 6075 (or a sequence having no more than one mutation, e.g., substitutions, additions or deletions), and / or a VLFWR4 amino acid sequence of SEQ ID NO: 6076.

[0179] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6014, the VHFWR2 amino acid sequence of SEQ ID NO:6015, the VHFWR3 amino acid sequence of SEQ ID NO:6016, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6017.

[0180] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6014 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6015 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6016 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6017.

[0181] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6077, the VLFWR2 amino acid sequence of SEQ ID NO:6078, the VLFWR3 amino acid sequence of SEQ ID NO:6079, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6080.

[0182] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO:6077 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO:6078 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO:6079 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO:6080.

[0183] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6018, the VHFWR2 amino acid sequence of SEQ ID NO:6019, the VHFWR3 amino acid sequence of SEQ ID NO:6020, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6021.

[0184] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6018 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6019 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6020 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6021.

[0185] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6081, the VLFWR2 amino acid sequence of SEQ ID NO:6082, the VLFWR3 amino acid sequence of SEQ ID NO:6083, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6084.

[0186] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO:6081 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO:6082 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO:6083 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO:6084.

[0187] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6022, the VHFWR2 amino acid sequence of SEQ ID NO:6023, the VHFWR3 amino acid sequence of SEQ ID NO:6024, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6025.

[0188] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO: 6022 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6023 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6024 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO: 6025.

[0189] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6085, the VLFWR2 amino acid sequence of SEQ ID NO:6086, the VLFWR3 amino acid sequence of SEQ ID NO:6087, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6088.

[0190] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6085 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6086 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6087 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6088.

[0191] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6026, the VHFWR2 amino acid sequence of SEQ ID NO:6027, the VHFWR3 amino acid sequence of SEQ ID NO:6028, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6029.

[0192] In some embodiments, the antigen-binding domain targeting NKp30 is selected from the group consisting of the VHFWR1 amino acid sequence of SEQ ID NO: 6026 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR2 amino acid sequence of SEQ ID NO: 6027 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR3 amino acid sequence of SEQ ID NO: 6028 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR4 amino acid sequence of SEQ ID NO: 6029 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR5 amino acid sequence of SEQ ID NO: 6030 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR6 amino acid sequence of SEQ ID NO: 6031 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR7 amino acid sequence of SEQ ID NO: 6032 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), the VHFWR8 amino acid sequence of SEQ ID NO: 6033 (or a sequence having no more than 1, 2, R3 amino acid sequence (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or fewer mutations, e.g., substitutions, additions, or deletions), and / or a VH comprising the VHFWR4 amino acid sequence of SEQ ID NO:6029.

[0193] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6089, the VLFWR2 amino acid sequence of SEQ ID NO: 6090, the VLFWR3 amino acid sequence of SEQ ID NO: 6091, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6092.

[0194] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6089 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6090 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6091 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6092.

[0195] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6030, the VHFWR2 amino acid sequence of SEQ ID NO: 6032, the VHFWR3 amino acid sequence of SEQ ID NO: 6033, and / or the VHFWR4 amino acid sequence of SEQ ID NO: 6034.

[0196] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO: 6030 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6032 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6033 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO: 6034.

[0197] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO:6093, the VLFWR2 amino acid sequence of SEQ ID NO:6094, the VLFWR3 amino acid sequence of SEQ ID NO:6095, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6096.

[0198] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6093 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6094 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6095 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6096.

[0199] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6035, the VHFWR2 amino acid sequence of SEQ ID NO:6036, the VHFWR3 amino acid sequence of SEQ ID NO:6037, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6038.

[0200] In some embodiments, the antigen binding domain targeting NKp30 is SEQ ID NO: 603 6035 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR1 amino acid sequence of SEQ ID NO: 6036 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO: 6037 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations, e.g., substitutions, additions, or deletions therefrom), and / or a VHFWR4 amino acid sequence of SEQ ID NO: 6038.

[0201] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6039, the VHFWR2 amino acid sequence of SEQ ID NO: 6040, the VHFWR3 amino acid sequence of SEQ ID NO: 6041, and / or the VHFWR4 amino acid sequence of SEQ ID NO: 6042.

[0202] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO: 6039 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6040 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6041 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO: 6042.

[0203] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6097, the VLFWR2 amino acid sequence of SEQ ID NO: 6098, the VLFWR3 amino acid sequence of SEQ ID NO: 6099, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6100.

[0204] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6097 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6098 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6099 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6100.

[0205] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6043, the VHFWR2 amino acid sequence of SEQ ID NO:6044, the VHFWR3 amino acid sequence of SEQ ID NO:6045, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6046.

[0206] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6043 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6044 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6045 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6046.

[0207] In some embodiments, the antigen binding domain targeting NKp30 is SEQ ID NO:610 6103, and / or the VLFWR4 amino acid sequence of SEQ ID NO:6104.

[0208] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6101 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6102 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6103 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6104.

[0209] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6047, the VHFWR2 amino acid sequence of SEQ ID NO:6048, the VHFWR3 amino acid sequence of SEQ ID NO:6049, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6050.

[0210] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO: 6047 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6048 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6049 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO: 6050.

[0211] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6105, the VLFWR2 amino acid sequence of SEQ ID NO: 6106, the VLFWR3 amino acid sequence of SEQ ID NO: 6107, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6108.

[0212] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6105 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6106 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6107 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6108.

[0213] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6051, the VHFWR2 amino acid sequence of SEQ ID NO:6052, the VHFWR3 amino acid sequence of SEQ ID NO:6053, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6054.

[0214] In some embodiments, the antigen-binding domain targeting NKp30 is selected from the group consisting of the VHFWR1 amino acid sequence of SEQ ID NO: 6051 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6052 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6053 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR4 amino acid sequence of SEQ ID NO: 6054 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR5 amino acid sequence of SEQ ID NO: 6055 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR6 amino acid sequence of SEQ ID NO: 6056 (or a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 or less mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR7 amino acid sequence of SEQ ID NO: 6057 (or a sequence having 1, 2, 3, 4, A VH having the following mutations, e.g., substitutions, additions, or deletions), and / or the VHFWR4 amino acid sequence of SEQ ID NO: 6054.

[0215] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6109, the VLFWR2 amino acid sequence of SEQ ID NO: 6110, the VLFWR3 amino acid sequence of SEQ ID NO: 6111, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6112.

[0216] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6109 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6110 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6111 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6112.

[0217] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6055, the VHFWR2 amino acid sequence of SEQ ID NO:6056, the VHFWR3 amino acid sequence of SEQ ID NO:6057, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6058.

[0218] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VH comprising a VHFWR1 amino acid sequence of SEQ ID NO:6055 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO:6056 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO:6057 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations therefrom, e.g., substitutions, additions, or deletions), and / or a VHFWR4 amino acid sequence of SEQ ID NO:6058.

[0219] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6113, the VLFWR2 amino acid sequence of SEQ ID NO: 6114, the VLFWR3 amino acid sequence of SEQ ID NO: 6115, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6116.

[0220] In some embodiments, an antigen-binding domain targeting NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6113 (or a sequence having no more than one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6114 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6115 (or a sequence having no more than one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6116.

[0221] In some embodiments, the antigen-binding domain targeting NKp30 comprises a VH comprising the heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO:6059, the VHFWR2 amino acid sequence of SEQ ID NO:6060, the VHFWR3 amino acid sequence of SEQ ID NO:6061, and / or the VHFWR4 amino acid sequence of SEQ ID NO:6062.

[0222] In some embodiments, the antigen-binding domain that targets NKp30 comprises the VHFWR1 amino acid sequence of SEQ ID NO: 6059 (or 1, 2, 3, 4, 5, or 6 or more amino acids therefrom). 6060 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR2 amino acid sequence of SEQ ID NO: 6060 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations, e.g., substitutions, additions, or deletions therefrom), the VHFWR3 amino acid sequence of SEQ ID NO: 6061 (or a sequence having no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 mutations, e.g., substitutions, additions, or deletions), and / or the VHFWR4 amino acid sequence of SEQ ID NO: 6062.

[0223] In some embodiments, an antigen-binding domain that targets NKp30 comprises a VL comprising the light chain framework region 1 (VLFWR1) amino acid sequence of SEQ ID NO: 6117, the VLFWR2 amino acid sequence of SEQ ID NO: 6118, the VLFWR3 amino acid sequence of SEQ ID NO: 6119, and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6120.

[0224] In some embodiments, an antigen-binding domain that targets NKp30 comprises a VL comprising the VLFWR1 amino acid sequence of SEQ ID NO: 6117 (or a sequence having only one, two, or three mutations, e.g., substitutions, additions, or deletions), the VLFWR2 amino acid sequence of SEQ ID NO: 6118 (or a sequence having only one mutation, e.g., substitutions, additions, or deletions), the VLFWR3 amino acid sequence of SEQ ID NO: 6119 (or a sequence having only one mutation, e.g., substitutions, additions, or deletions), and / or the VLFWR4 amino acid sequence of SEQ ID NO: 6120.

[0225] In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO:6148 (or an amino acid sequence having at least about 77%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:6148). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO:6149 (or an amino acid sequence having at least about 77%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:6149). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VL comprising the amino acid sequence of SEQ ID NO:6150 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO:6150). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO:6148. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6149. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VL comprising the amino acid sequence of SEQ ID NO: 6150.

[0226] In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6148, and a VL comprising the amino acid sequence of SEQ ID NO: 6150. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6149, and a VL comprising the amino acid sequence of SEQ ID NO: 6150.

[0227] In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO:6151 (or an amino acid sequence having at least about 77%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:6151). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO:6152 (or an amino acid sequence having at least about 77%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO:6152). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VL comprising the amino acid sequence of SEQ ID NO:6153 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO:6153). In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6151. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6152. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VL comprising the amino acid sequence of SEQ ID NO: 6153.

[0228] In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6151, and a VL comprising the amino acid sequence of SEQ ID NO: 6153. In some embodiments, the antigen-binding domain that targets NKp30 comprises a VH comprising the amino acid sequence of SEQ ID NO: 6152, and a VL comprising the amino acid sequence of SEQ ID NO: 6153.

[0229] In some embodiments, the antigen-binding domain that targets NKp30 comprises an scFv. In some embodiments, the scFv comprises an amino acid sequence selected from SEQ ID NOs: 6187-6190, or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity thereto.

[0230] [Table 1-1]

[0231] [Table 1-2]

[0232] [Table 2-1]

[0233] [Table 2-2]

[0234] [Table 2-3]

[0235] [Table 3-1]

[0236] [Table 3-2]

[0237] [Table 3-3]

[0238] [Table 4-1]

[0239] [Table 4-2]

[0240] [Table 4-3]

[0241] [Table 4-4]

[0242] [Table 4-5]

[0243] [Table 5-1]

[0244] [Table 5-2]

[0245] In some embodiments, the NK cell engager is an antigen binding domain that binds to NKp46 (e.g., NKp46 present, e.g., expressed or displayed on the surface of an NK cell) and comprises any of the CDR amino acid sequences, framework region (FWR) amino acid sequences, or variable region amino acid sequences disclosed in Table 15. In some embodiments, binding of the NK cell engager, e.g., an antigen binding domain that binds to NKp46, to an NK cell activates the NK cell. An antigen binding domain that binds to NKp46 (e.g., NKp46 present, e.g., expressed or displayed on the surface of an NK cell) may be referred to as targeting NKp46, the NK cell, or both.

[0246] In some embodiments, the NK cell engager is an antigen binding domain that binds to NKG2D (e.g., NKG2D present, e.g., expressed or displayed on the surface of an NK cell) and comprises any of the CDR amino acid sequences, framework region (FWR) amino acid sequences, or variable region amino acid sequences disclosed in Table 15. In some embodiments, binding of the NK cell engager, e.g., an antigen binding domain that binds to NKG2D, to an NK cell activates the NK cell. An antigen binding domain that binds to NKG2D (e.g., NKG2D present, e.g., expressed or displayed on the surface of an NK cell) may be referred to as targeting NKG2D, the NK cell, or both.

[0247] In some embodiments, the NK cell engager comprises an antigen-binding domain that binds to CD16 (e.g., CD16 that is present, e.g., expressed or displayed, on the surface of an NK cell). and comprises any CDR amino acid sequence, framework region (FWR) amino acid sequence, or variable region amino acid sequence disclosed in Table 15. In some embodiments, binding of an antigen-binding domain that binds to a NK cell engager, e.g., CD16, to a NK cell activates the NK cell. An antigen-binding domain that binds to CD16 (e.g., CD16 present, e.g., expressed or displayed, on the surface of a NK cell) may be referred to as targeting CD16, the NK cell, or both.

[0248] [Table 6-1]

[0249] [Table 6-2]

[0250] In one embodiment, the NK cell engager is a ligand for NKp30, e.g., B7-6, e.g., DLKVEMMAGGTQITPLNDNVTIFCNIFYSQPLNITSMGITTWFWKSLTFDKEVKVFEFFGDHQEAFRPGAIVSPWRLKSGDASLRPGIQLEEAGEYRCEVVVTPLKAQGTVQLEVVASPASRLLLDQVGMKENEDKYMCESSGFYPEAINITWEKQTQKFPHPIEISEDVITGPTIKNMDGTFNVTSCLKLNSSQEDPGTVYQCVVRHASLHTPLRSNFTLTAARHSLSETEKTDNFS (SEQ ID NO: 7233), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 7233.

[0251] In other embodiments, the NK cell engager is a ligand for viral HA, NKp44 or NKp46. Viral hemagglutinin (HA) is a glycoprotein on the surface of a virus. The HA protein allows the virus to bind to the membrane of a cell via sialic acid sugar moieties, which contributes to the fusion of the viral membrane with the cell membrane (see, e.g., Eur J Immunol. 2001 Sep;31(9):2680-9, "Recognition of viral hemagglutinins by "NKp44 but not by NKp30"; and Nature 2001 Feb 22;409(6823):1055-60, "Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells, the contents of each of which are hereby incorporated by reference.

[0252] In other embodiments, the NK cell engager is a ligand for NKG2D selected from MICA, MICB, or ULBP1, e.g., (i) MICA: EPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQGQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHE DNSTRSSQHFYYDGELFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPPMVNVTRSEASEGNITV An amino acid sequence of TCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGEEQRFTCYMEHSGNHSTHPVPSGKVLVLQSHW (SEQ ID NO: 7234), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7234, but no more than 5, 10, or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions). Including, (ii) MICB: AEPHSLRYNLMVLSQDESVQSGFLAEGHLDGQPFLRYDRQKRRAKPQGQWAEDVLGAKTWDTETEDLTENGQDLRRTLTHIKDQKGGLHSLQEIRVCEIHEDSSTRGSRHFY YDGELFLSQNLETQESTVPQSSRAQTLAMNVTNFWKEDAMKTKTHYRAMQADCLQKLQRYLKSGVAIRRTVPPMVNVTCSEVSEGNITVTCRASSFYPRNITLTWRQDGVSL An amino acid sequence of SHNTQQWGDVLPDGNGTYQTWVATRIRQGEEQRFTCYMEHSGNHGTHPVPSGKVLVLQSQRTD (SEQ ID NO: 7235), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7235, but no more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions). Contains, or (iii) ULBP1 GWVDTHCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCVNHKAKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQMLDPTKPPSLAPG (SEQ ID NO: 7236), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 7236. Includes.

[0253] In other embodiments, the NK cell engager is a ligand of DNAM1 selected from NECTIN2 or NECL5, e.g., (i) NECTIN2 is QDVRVQVLPEVRGQLGGTVELPCHLLPPVPGLYISLVTWQRPDAPANHQNVAAFHPKMGPSFPSPKPGSERLSFVSAKQSTGQDTEAELQDATLALHGLTVEDEGNYTCEFATFPKGSVRGMTW LRVIAKPKNQAEAQKVTFSQDPTTVALCISKEGRPPARISWLSSLDWEAKETQVSGTLAGTVTVTSRFTLVPSGRADGVTVTCKVEHESFEEPALIPVTLSVRYPPEVSISGYDDNWYLGRTDA TLSCDVRSNPEPTGYDWSTTSGTFPTSAVAQGSQLVIHAVDSLFNTTFVCTVTNAVGMGRAEQVIFVRETPNTAGAGATGG (SEQ ID NO: 7237), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7237, but no more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions); or (ii) NECL5 WPPPGTGDVVVQAPTQVPGFLGDSVTLPCYLQVPNMEVTHVSQLTWARHGESGSMAVFHQTQGPSYSESKRLEFVAARLGAELRNASLRMFGLRVEDEGNYTCLFVTFPQGSRSVDIWLRVL AKPQNTAEVQKVQLTGEPVPMARCVSTGGRPPAQITWHSDLGMPNTSQVPGFLSGTVTVTSLWILVPSSQVDGKNVTCKVEHESFEKPQLLTVNLTVYYPPEVSISGYDNNWYLGQNEATL TCDARSNPEPTGYNWSTTMGPLPPFAVAQGAQLLIRPVDKPINTTLICNVTNALGARQAELTVQVKEGPPSEHSGISRN (SEQ ID NO: 7238), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 7238.

[0254] In yet other embodiments, the NK cell engager is a ligand for DAP10, an adaptor for NKG2D (see, e.g., Proc Natl Acad Sci US A. 2005 May 24;102(21):7641-7646; and Blood, 15 September 2011 Volume 118, Number 11, the entire contents of each of which are hereby incorporated by reference herein).

[0255] In other embodiments, the NK cell engager is a ligand of CD16 that is a CD16a / b ligand, e.g., a CD16a / b ligand that further comprises an antibody Fc region (see, e.g., Front Immunol. 2013;4:76, which discusses how antibodies use Fc to trigger NK cells through CD16, the contents of which are incorporated herein in their entirety).

[0256] In other embodiments, the NK cell engager is a ligand for CRTAM, which is NECL2, for example, NECL2 has the amino acid sequence: QNLFTKDVTVIEGEVATISCQVNKSDDSVIQLLNPNRQTIYFRDFRPLKDSRFQLLNFSSSELKVSLTNVSISDEGRYFCQLYTDPPQESYTTITVLVPPRNLMIDIQKDTAVEGEEIEVN CTAMASKPATTIRWFKGNTELKGKSEVEEWSDMYTVTSQLMLKVHKEDDGVPVICQVEHPAVTGNLQTQRYLEVQYKPQVHIQMTYPLQGLTREGDALELTCEIAIGKPQPVMVTWVRVDDEM PQHAVLSGPNLFINNLNKTDNGTYRCEASNIVGKAHSDYMLYVYDPPTTIPPPTTTTTTTTTTTTTILTIITDSRAGEEGSIRAVDH (SEQ ID NO: 7239), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7239, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0257] In other embodiments, the NK cell engager is a ligand for CD27, which is CD70, for example, CD70 has the amino acid sequence: QRFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGGPALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSSTTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQRLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP (Sequence Number 7240), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid alteration relative to the amino acid sequence of SEQ ID NO: 7240, but not more than 5, 10 or 15 alterations (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0258] In other embodiments, the NK cell engager is a ligand for PSGL1 that is L-selectin (CD62L), for example, L-selectin has the amino acid sequence: WTYHYSEKPMNWQRARRFCRDNYTDLVAIQNKAEIEYLEKTLPFSRSYYWIGIRKIGGIWTWVGTNKSLTEEAENWGDGEPNNKKNKEDCVEIYIKRNKDAGKWNDDACHKL KAALCYTASCQPWSCSGHGECVEIINNYTCNCDVGYYGPQCQFVIQCEPLEAPELGTMDCTHPLGNFSFSSQCAFSCSEGTNLTGIEETTCGPFGNWSSPEPTCQVIQCEPLS APDLGIMNCSPLASFSFTSACTFICSEGTELIGKKKTICESSGIWSNPSPICQKLDKSFSMIKEGDYN (SEQ ID NO: 7241), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7241, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0259] In other embodiments, the NK cell engager is a ligand for CD96, which is NECL5, for example, NECL5 has the amino acid sequence: WPPPGTGDVVVQAPTQVPGFLGDSVTLPCYLQVPNMEVTHVSQLTWARHGESGSMAVFHQTQGPSYSESKRLEFVAARLGAELRNASLRMFGGLRVEDEGNYTCLFVTFPQGSRSVDIWLR VLAKPQNTAEVQKVQLTGEPVPMARCVSTGGRPPAQITWHSDLGMPNTSQVPGFLSGTVTVTSLWILVPSSQVDGKNVTCKVEHESFEKPQLLTVNLTVYYPPEVSISGYDNNWYLGQN EATLTCDARSNPEPTGYNWSTTMGPLPPFAVAQGAQLLIRPVDKPINTTLICNVTNALGARQAELTVQVKEGPPSEHSGISRN (SEQ ID NO: 7238), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7238, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0260] In other embodiments, the NK cell engager is a ligand for CD100 (SEMA4D), which is CD72, for example, CD72 has the amino acid sequence: RYLQVSQQLQQTNRVLEVTNSSLRQQLRLKITQLGQSAEDLQGSRRELAQSQEALQVEQRAHQAAEGQLQACQADRQKTKETLQSEEQQRRALEQKLSNMENRLKPFFTCGSADTCCPSGWIMHQKSCFYISLTSKNWQESQKQCETLSSKLATFSEIYPQSHSYYFLNSLLPNGGSGNSYWTGLSSNKDWKLTDDTQRTRTYAQSSKCNKVHKTWSWWTLESESCRSSLPYICEMTAFRFPD (SEQ ID NO:7242), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO:7242, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0261] In other embodiments, the NK cell engager is a ligand for NKp80 that is CLEC2B (AICL), for example, CLEC2B (AICL) has the amino acid sequence: KLTRDSQSLCPYDWIGFQNKCYYFSKEEGDWNSSKYNCSTQHADLTIIDNIEEMNFLRRYKCSSDHWIGLKMAKNRTGQWVDGATFTKSFGMRGSEGCAYLSDDGAATARCYTERKWICRKRIH (SEQ ID NO:7243), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO:7243.

[0262] In other embodiments, the NK cell engager is a ligand for CD244, which is CD48, for example, CD48 has the amino acid sequence: QGHLVHMTVVSGSNVTLNISESLPENYKQLTWFYTFDQKIVEWDSRKSKYFESKFKGRVRLDPQSGALYISKVQKEDNSTYIMRVLKKTGNEQEWKIKLQVLDPVPKPVIKIEKIEDMDDNCYLKLSCVIPGESVNYTWYGDKRPFPKELQNSVLETTLMPHNYSRCYTCQVSNSVSSKNGTVCLSPPCTLARS (SEQ ID NO: 7244), a fragment thereof, or an amino acid sequence substantially identical thereto (e.g., 95% to 99.9% identical thereto, or an amino acid sequence having at least one amino acid change relative to the amino acid sequence of SEQ ID NO: 7244, but not more than 5, 10 or 15 changes (e.g., substitutions, deletions, or insertions, e.g., conservative substitutions).

[0263] In some embodiments, the NK cell engager is the viral hemagglutinin (HA), which is a glycoprotein found on the surface of influenza viruses. It is responsible for the binding of the virus to cells in the upper respiratory tract or cells that have sialic acid on their membranes, such as red blood cells. HA has at least 18 different antigens. These subtypes are named H1 to H18. NCRs can recognize viral proteins. It has been shown that NKp46 can interact with influenza HA and HA-NA of paramyxoviruses, including Sendai virus and Newcastle disease virus. Besides NKp46, NKp44 can also functionally interact with HA of different influenza subtypes.

[0264] antibody molecule In certain embodiments, the anti-NKp30 antibody molecule is a monospecific antibody molecule and binds to a single epitope on NKp30. For example, a monospecific antibody molecule has multiple immunoglobulin variable domain sequences that each bind to the same epitope.

[0265] In another embodiment, the anti-NKp30 antibody molecule is a multispecific or multifunctional antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, a first of the plurality of immunoglobulin variable domain sequences having binding specificity for a first epitope and a second of the plurality of immunoglobulin variable domain sequences having binding specificity for a second epitope. In one embodiment, the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap. In one embodiment, the first and second epitopes do not overlap. In one embodiment, the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In one embodiment, the multispecific antibody molecule comprises a third, fourth, or fifth immunoglobulin variable domain. In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule.

[0266] In one embodiment, the multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence having binding specificity for a first epitope and a second immunoglobulin variable domain sequence having binding specificity for a second epitope. In one embodiment, the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In one embodiment, the first and second epitopes overlap. In one embodiment, the first and second epitopes do not overlap. In one embodiment, the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In one embodiment, a bispecific antibody molecule comprises heavy and light chain variable domain sequences having binding specificity for a first epitope and heavy and light chain variable domain sequences having binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope, and a half antibody, or fragment thereof, having binding specificity for a second epitope. In one embodiment, a bispecific antibody molecule comprises an scFv or Fab, or fragment thereof, having binding specificity for a first epitope, and an scFv or Fab, or fragment thereof, having binding specificity for a second epitope.

[0267] In one embodiment, antibody molecules include antigen-binding fragments of antibodies (e.g., Fab, F(ab')2, and Fv), in addition to diabodies and single chain molecules. For example, an antibody molecule can include a heavy (H) chain variable domain sequence (abbreviated herein as VH), and a light (L) chain variable domain sequence (abbreviated herein as VL). In one embodiment, an antibody molecule includes or consists of a heavy chain and a light chain (referred to herein as a half antibody. In another example, an antibody molecule includes two heavy (H) chain variable domain sequences and two light (L) chain variable domain sequences, thereby forming two antigen-binding sites, e.g., Fab, Fab', F(ab')2, Fc, Fd, Fd', Fv, single chain antibodies (e.g., scFv), single variable domain antibodies, diabodies (Dab) (bivalent and bispecific), and chimeric (e.g., humanized) antibodies, which can be produced by modification of full-length antibodies or can be derived using recombinant DNA technology. These functional antibody fragments retain the ability to selectively bind to their respective antigens or receptors. The antibodies and antibody fragments can be from any class of antibodies, including but not limited to IgG, IgA, IgM, IgD, and IgE, and from any subclass of antibodies (e.g., IgG1, IgG2, IgG3, and IgG4). Preparations of antibody molecules can be monoclonal or polyclonal. The antibody molecules can also be human, humanized, CDR-grafted, or in vitro generated antibodies. The antibodies can have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. The antibodies can also have a light chain selected from, for example, kappa or lambda. The term "immunoglobulin" (Ig) is used interchangeably herein with the term "antibody."

[0268] Examples of antigen-binding fragments of an antibody molecule include (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a diabody (dAb) fragment consisting of a VH domain; (vi) a camel or camelized variable domain; (vii) a single chain Fv (scFv), see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883; (viii ... These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0269] Antibody molecules include intact molecules as well as functional fragments thereof. The constant regions of antibody molecules can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function).

[0270] The antibody molecule may also be a single domain antibody. Single domain antibodies may include antibodies whose complementary determining regions are parts of a single domain polypeptide. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional four chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. The single domain antibody may be any in the art or any future single domain antibody. The single domain antibody may be derived from any species including, but not limited to, mouse, human, camel, llama, fish, shark, goat, rabbit, and cow. According to another aspect of the invention, the single domain antibody is a naturally occurring single domain antibody known as a heavy chain antibody devoid of light chains. Such single domain antibodies are disclosed, for example, in WO9404678. For reasons of clarity, this variable domain derived from a heavy chain antibody naturally devoid of light chains is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such VHH molecules can be derived from antibodies produced in Camelidae species, such as camel, llama, dromedary, alpaca and guanaco. Other non-Camelidae species may produce heavy chain antibodies naturally devoid of light chains, and such VHHs are within the scope of the present invention.

[0271] The VH and VL regions can be further divided into regions of hypervariability called "complementarity determining regions" (CDRs), interspersed with regions that are more conserved called "framework regions" (FR or FW).

[0272] The extent of framework regions and CDRs have been precisely defined in a number of ways (see, e.g., Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242; Chothia, C. et al., (1987) J. Mol. Biol. 196:901-917; and the AbM definitions used by Oxford Molecular's AbM antibody modeling software. Generally, see, e.g., "Protein Sequence and Structure Analysis of Antibody Variable Domains,” Antibody Engineering Lab Manual (Duebel, S. and Kontermann, R., eds., Springer-Verlag, Heidelberg).

[0273] The terms "complementarity determining region" and "CDR" as used herein refer to the sequence of amino acids in an antibody variable region that confers antigen specificity and binding affinity. Generally, there are three CDRs in each heavy chain variable region (HCDR1, HCDR2, HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, LCDR3).

[0274] The precise amino acid sequence boundaries of a given CDR can be determined by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th ed., Public Health Service, National The CDRs may be determined using any of a number of known schemes, including those described in Al-Lazikani et al., (1997) JMB 273, pp. 927-948 (the "Chothia" numbering scheme), Institutes of Health, Bethesda, MD (the "Kabat" numbering scheme). As used herein, CDRs defined according to the "Chothia" numbering scheme are sometimes referred to as "hypervariable loops."

[0275] For example, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3), and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under Chothia, the CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3), and the amino acid residues in the VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3).

[0276] Each VH and VL typically contains three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0277] The antibody molecule can be a polyclonal or a monoclonal antibody. The terms "monoclonal antibody" or "monoclonal antibody composition" as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies can be made by hybridoma technology or by methods that do not use hybridoma technology (e.g., recombinant methods).

[0278] Antibodies can be recombinantly produced, for example, by phage display or combinatorial methods. Phage display and combinatorial methods for generating antibodies are known in the art (see, e.g., Ladner et al., U.S. Pat. No. 5,223,409; Kang et al., International Publication No. WO 92 / 18619; Dower et al., International Publication No. WO 91 / 17271; Winter et al., International Publication No. WO 92 / 20791; Markland et al., International Publication No. WO 92 / 15679; Breitling et al., International Publication No. WO 93 / 01288; McCafferty et al., International Publication No. WO 92 / 01047; Garrard et al., International Publication No. WO 92 / 09690; Ladner et al., International Publication No. WO 90 / 02809; Fuchs et al., (1991) Bio / Technology 9:1370-1372; Hay et al., (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991) Bio / Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the entire contents of which are hereby incorporated by reference.

[0279] In one embodiment, the antibody is a fully human antibody (e.g., an antibody derived from a human immunoglobulin sequence). The non-human antibody may be a rodent (mouse or rat), goat, primate (e.g., monkey), or camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Methods for producing rodent antibodies are known in the art.

[0280] Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes instead of the mouse system. Spleen cells from these transgenic mice immunized with an antigen of interest are used to produce hybridomas secreting human mAbs with specific affinity for epitopes from human proteins (see, e.g., Wood et al., International Application WO 91 / 00906; Kucherlapati et al., PCT International Publication WO 91 / 10741; Lonberg et al., International Application WO 92 / 03918; Kay et al., International Application 92 / 03917; Lonberg, N. et al., 1994 Nature 368:856-859; Green, LL et al., 1994 Nature Genet. 7:13-21; Morrison, SL et al., 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al., 1993 Year Immunol 7:33-40; Tuaillon et al., 1993 PNAS 368:856-859; 90:3720-3724; Bruggeman et al., 1991 Eur J Immunol 21:1323-1326).

[0281] The antibody molecule may be one in which the variable region, or a part thereof, such as CDR, is generated in a non-human organism, such as a rat or a mouse. Chimeric, CDR-grafted, and humanized antibodies are within the scope of the present invention. Antibody molecules generated in a non-human organism, such as a rat or a mouse, and then modified, for example, in the variable framework or constant region, to reduce antigenicity in humans, are within the scope of the present invention.

[0282] An "effectively human" protein is one that does not substantially elicit a neutralizing antibody response, such as a human anti-mouse antibody (HAMA) response. HAMA can be problematic in many situations, for example, when an antibody molecule is administered repeatedly, for example, in the treatment of chronic or recurrent disease states. HAMA responses can render repeated antibody administration potentially ineffective due to increased clearance of the antibody from serum (see, e.g., Saleh et al., Cancer Immunol. Immunother., 32:180-190 (1990)), and also due to potential allergic reactions (see, e.g., LoBuglio et al., Hybridoma, 5:5117-5123 (1986)).

[0283] Chimeric antibodies can be produced by recombinant DNA techniques known in the art (Robinson et al., International Publication No. PCT / US86 / 02269; Akira et al., European Patent Application No. 184,187; Taniguchi, M., European Patent Application No. 171,496; Morrison et al., European Patent Application No. 173,494; Neuberger et al., International Publication WO 86 / 01533; Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent Application No. 125,023; Better et al., (1988 Science 240:1041-1043); Liu et al., (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al., (1987) PNAS 84:214-218; Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al., (1985) Nature 314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst. 80:1553-1559).

[0284] A humanized or CDR-grafted antibody has at least one or two, but generally all three, recipient CDRs (of the heavy and / or light immunoglobulin chains) replaced with donor CDRs. The antibody may have at least a portion of a non-human CDR replaced, or only a portion of the CDRs replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding to the antigen. Preferably, the donor is a rodent antibody, e.g., a rat or mouse antibody, and the recipient is a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDRs is called the "donor" and the immunoglobulin providing the framework is called the "acceptor". In one embodiment, the donor immunoglobulin is non-human (e.g., rodent). The acceptor framework is a naturally occurring (e.g., human) framework or consensus framework, or a sequence that is about 85% or higher, preferably 90%, 95%, 99% or more identical thereto.

[0285] As used herein, the term "consensus sequence" refers to a sequence formed from the amino acids (or nucleotides) that occur most frequently in a family of related sequences (see, e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid that occurs most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. "Consensus framework" refers to the framework region in the consensus immunoglobulin sequence.

[0286] Antibody molecules can be humanized by methods known in the art (see, e.g., Morrison, SL, 1985, Science 229:1202-1207; Oi et al., 1986, BioTechniques 4:214; and Queen et al., U.S. Pat. Nos. 5,585,089, 5,693,761 and 5,693,762, the contents of all of which are hereby incorporated by reference).

[0287] Humanized or CDR-grafted antibody molecules can be produced by CDR-grafting or CDR-replacement, in which one, two or all CDRs of an immunoglobulin chain can be replaced. See, for example, U.S. Patent No. 5,225,539; Jones et al., 1986 Nature 321:552-525; Verhoeyan et al., 1988 Science 239:1534; Beidler et al., 1988 J. Immunol. 141:4053-4060; Winter, U.S. Patent No. 5,225,539, the contents of all of which are hereby expressly incorporated herein by reference. Winter describes a CDR-grafting method that can be used to prepare the humanized antibodies of the present invention (UK Patent Application No. 2188638A filed March 26, 1987; Winter, U.S. Patent No. 5,225,539), the contents of which are hereby expressly incorporated herein by reference.

[0288] Humanized antibody molecules in which specific amino acids are substituted, deleted or added are also within the scope of the present invention. Criteria for selecting amino acids from the donor are described in U.S. Patent No. 5,585,089, e.g., U.S. Patent No. 5,585,089, columns 12-16, e.g., U.S. Patent No. 5,585,089, columns 12-16, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al., EP 519596 A1, published December 23, 1992.

[0289] The antibody molecule may be a single chain antibody. Single chain antibodies (scFV) may be engineered (see, e.g., Colcher, D. et al. (1999) Ann NY Acad Sci 880:263-80; and Reiter, Y. (1996) Clin (See Cancer Res 2:245-52.) Single chain antibodies can dimerize or multimerize to generate multivalent antibodies having specificities for different epitopes of the same target protein.

[0290] In yet other embodiments, the antibody molecule has a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE heavy chain constant regions, in particular, for example, IgG1, IgG2, IgG3, and IgG4 (e.g., human) heavy chain constant regions. In another embodiment, the antibody molecule has a light chain constant region selected from, for example, kappa or lambda (e.g., human) light chain constant regions. The constant region can be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, number of cysteine ​​residues, effector cell function, and / or complement function). In one embodiment, the antibody has effector function and can fix complement. In another embodiment, the antibody does not recruit effector cells and does not fix complement. In another embodiment, the antibody has reduced or no ability to bind to Fc receptors. For example, it may be an isotype or subtype, fragment or other mutant that does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

[0291] Methods for modifying antibody constant regions are known in the art.Antibodies with modified functions, such as modified affinity for effector ligands, such as FcR on cells, or C1 component of complement, can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see, for example, EP388,151A1, U.S. Patent No. 5,624,821 and U.S. Patent No. 5,648,260, the contents of all of which are hereby incorporated by reference).Similar types of modifications can be described that reduce or eliminate these functions when applied to mouse, or other species of immunoglobulins.

[0292] An antibody molecule can be derivatized or linked to another functional molecule (e.g., another peptide or protein). As used herein, a "derivatized" antibody molecule is an antibody molecule that has been modified. Methods of derivatization include, but are not limited to, the addition of fluorescent moieties, radionucleotides, toxins, enzymes, or affinity ligands, such as biotin. Thus, the antibody molecules of the present invention are intended to include derivatized and otherwise modified forms of the antibodies described herein, including immunoadhesion molecules. For example, an antibody molecule can be functionally linked (by chemical coupling, genetic fusion, non-covalent association, or otherwise) to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and / or a protein or peptide that can mediate the association of the antibody or antibody portion with another molecule (e.g., a streptavidin core region or a polyhistidine tag).

[0293] One type of derivatized antibody molecule is produced by crosslinking two or more antibodies (of the same or different types, e.g., to create bispecific antibodies). Suitable crosslinkers include those that are heterobifunctional, having two separately reactive groups separated by a suitable spacer (e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) or homobifunctional (e.g., disuccinimidyl suberate). Such linkers are available from Pierce Chemical Company, Rockford, Ill.

[0294] Multispecific or multifunctional antibody molecules Exemplary structures of multispecific and multifunctional molecules as defined herein are described throughout. Exemplary structures are found in Weidle U et al. (2013) The Intriguing Options of Multispecific Antibodies. Formats for Treatment of Cancer. Genomics & Proteomics 10: 1-18 (2013); and Spiess C et al. (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular Immunology 67: 95-106, the entire contents of each of which are hereby incorporated by reference herein.

[0295] In embodiments, a multispecific antibody molecule may contain more than one antigen-binding site, where different sites are specific for different antigens. In embodiments, a multispecific antibody molecule may bind to more than one (e.g., two or more) epitopes on the same antigen. In embodiments, a multispecific antibody molecule contains an antigen-binding site specific for a target cell (e.g., a cancer cell) and a different antigen-binding site specific for an immune effector cell. In one embodiment, a multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibody molecules can be classified into five different structural groups: (i) bispecific immunoglobulin G (BsIgG), (ii) IgG with additional antigen-binding moieties appended, (iii) bispecific antibody fragments, (iv) bispecific fusion proteins, and (v) bispecific antibody conjugates.

[0296] BsIgG is a monovalent format for each antigen. Exemplary BsIgG formats include, but are not limited to, crossMab, DAF (two-in-one), DAF (four-in-one), DutaMab, DT-IgG, knobs-in-holes common LC, knobs-in-hole assembly, charge pair, Fab arm exchange, SEED body, triomab, LUZ-Y, Fcab, kappa lambda body, orthogonal Fab. Spiess et al., Mol. Immunol. 67(2015):95-106. Exemplary BsIgGs include catumaxomab (Fresenius Biotech, Trion Pharma, Neopharm), which contains an anti-CD3 arm and an anti-EpCAM arm, and ertumaxomab (Neovii Biotech, Fresenius Biotech), which targets CD3 and HER2. In some embodiments, the BsIgG comprises a heavy chain engineered for heterodimerization. For example, the heavy chain can be engineered for heterodimerization using a "knobs-into-holes" strategy, the SEED platform, a common heavy chain (e.g., in a κλ body), and the use of a heterodimeric Fc region. See Spiess et al., Mol. Immunol. 67(2015):95-106. Strategies that have been used to avoid homodimeric heavy chain pairing in BsIgG include knobs-in-holes, duobodies, azymetric, charge-pair, HA-TF, SEED bodies, and differential Protein A affinity. See Id. BsIgG can be produced by separate expression of component antibodies in different host cells and subsequent purification / assembly into BsIgG. BsIgG can also be produced by expression of component antibodies in a single host cell. BsIgG can be purified using affinity chromatography, for example, using Protein A and sequential pH elution.

[0297] IgGs with additional antigen-binding moieties added are another format of bispecific antibody molecules. For example, monospecific IgGs can be made bispecific by adding additional antigen-binding units to the monospecific IgG, e.g., at the N- or C-terminus of either the heavy or light chain. Exemplary additional antigen-binding units include single domain antibodies (e.g., variable heavy or variable light chains), engineered protein scaffolds, and paired antibody variable domains (e.g., single chain variable fragments or variable fragments). See ibid. Examples of added IgG formats include dual variable domain IgG (DVD-Ig), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, zybody, and DVI-IgG(4-in-1). See Spiess et al., Mol. Immunol. 67(2015):95-106. An example of an IgG-scFv is MM-141 (Merrimack Pharmaceuticals), which binds IGF-1R and HER3. Examples of DVD-Igs include ABT-981 (AbbVie), which binds IL-1α and IL-1β, and ABT-122 (AbbVie), which binds TNF and IL-17A.

[0298] Bispecific antibody fragments (BsAbs) are a format of bispecific antibody molecules that lack some or all of the antibody constant domains. For example, some BsAbs lack the Fc region. In embodiments, bispecific antibody fragments contain heavy and light chain regions connected by a peptide linker that allows efficient expression of the BsAb in a single host cell. Exemplary bispecific antibody fragments include, but are not limited to, nanobodies, nanobody-HAS, BiTEs, diabodies, DARTs, TandAbs, scDiabody, scDiabody-CH3, diabody-CH3, triple bodies, miniantibodies, minibodies, TriBi minibodies, scFv-CH3 KIH, Fab-scFv, scFv-CH-CL-scFv, F(ab')2, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, and intrabodies. See ibid. For example, the BiTE format includes tandem scFvs, where the component scFvs bind to CD3 on T cells and to a surface antigen on a cancer cell.

[0299] Bispecific fusion proteins include, for example, antibody fragments linked to other proteins to add additional specificity and / or functionality. An example of a bispecific fusion protein is immTAC, which contains an anti-CD3 scFv linked to an affinity matured T cell receptor that recognizes an HLA-presented peptide. In embodiments, the dock-and-lock (DNL) method can be used to generate bispecific antibody molecules with higher valency. Fusion to albumin-binding proteins or human serum albumin can also extend the serum half-life of antibody fragments. See ibid.

[0300] In embodiments, chemical conjugation, such as chemical conjugation of antibodies and / or antibody fragments, can be used to create BsAb molecules. See ibid. Exemplary bispecific antibody conjugates include the CovX body format, in which a low molecular weight drug is site-specifically conjugated to each Fab arm or to a single reactive lysine in an antibody or its fragment. In embodiments, the conjugation improves the serum half-life of the low molecular weight drug. An exemplary CovX body is CVX-241 (NCT01004822), which comprises an antibody conjugated to two short peptides that inhibit either VEGF or Ang2. See ibid.

[0301] Antibody molecules can be produced, for example, by recombinant expression of at least one or more components in a host system. Exemplary host systems include eukaryotic cells (e.g., mammalian cells, such as CHO cells, or insect cells, such as SF9 or S2 cells) and prokaryotic cells (e.g., E. coli). Bispecific antibody molecules can be produced by recombinant expression of at least one or more components in a host system. Exemplary host systems include eukaryotic cells (e.g., mammalian cells, such as CHO cells, or insect cells, such as SF9 or S2 cells) and prokaryotic cells (e.g., E. coli). Bispecific antibody molecules can be produced by separate expression of the components in a single host cell and subsequent purification / assembly. Alternatively, antibody molecules can be produced by expression of the components in a single host cell. Purification of bispecific antibody molecules can be performed by a variety of methods, such as affinity chromatography using, for example, Protein A and sequential pH elution. In other embodiments, affinity tags, such as histidine-containing tags, myc tags, or streptavidin tags, can be used for purification.

[0302] CDR-grafted scaffolds In an embodiment, the antibody molecule is a CDR-grafted scaffold domain. In an embodiment, the scaffold domain is based on a fibronectin domain, for example, a fibronectin type III domain. The overall fold of the fibronectin type III (Fn3) domain is closely related to that of the smallest functional antibody fragment, the variable domain of the antibody heavy chain. There are three loops at the end of Fn3, and the positions of the BC, DE and FG loops roughly correspond to those of CDR1, 2 and 3 of the VH domain of an antibody. Fn3 does not have disulfide bonds, and therefore, unlike antibodies and their fragments, Fn3 is stable under reducing conditions (see, for example, WO98 / 56915, WO01 / 64942, WO00 / 34784). The Fn3 domain can be modified or altered (e.g., using the CDRs or hypervariable loops described herein) to select domains that bind to, for example, antigens / markers / cells as described herein.

[0303] In embodiments, the scaffold domain, e.g., the folded domain, is based on a "minibody" scaffold created by deleting three beta strands from the heavy chain variable domain of an antibody, e.g., a monoclonal antibody (see, e.g., Tramontano et al., 1994, J Mol. Recognit. 7:9, and Martin et al., 1994, EMBO J. 13:5303-5309). A "minibody" can be used to display two hypervariable loops. In embodiments, the scaffold domain is a V-like domain (see, e.g., Coia et al., WO99 / 45110), or a domain derived from tendamistatin, a 74-residue six-stranded beta sheet sandwich held together by two disulfide bonds (see, e.g., McConnell and Hoess, 1995, J Mol. Biol. 250:460). For example, the loops of tendamistatin can be modified or altered (e.g., using CDRs or hypervariable loops) to select domains that bind to, for example, markers / antigens / cells described herein. Another exemplary scaffold domain is a beta-sandwich structure derived from the extracellular domain of CTLA-4 (see, e.g., WO00 / 60070).

[0304] Other exemplary scaffold domains include, but are not limited to, T cell receptors, MHC proteins, extracellular domains (e.g., fibronectin type III repeats, EGF repeats), protease inhibitors (e.g., Kunitz domains, ecotin, and BPTI, etc.), TPR repeats, trifoil structures, zinc finger domains, DNA binding proteins, particularly monomeric DNA binding proteins, RNA binding proteins, enzymes, such as proteases (particularly inactivating proteases), RNases, chaperones, such as thioredoxin, and heat shock proteins, and intracellular signaling domains (e.g., SH2 and SH3 domains). See, e.g., U.S. Patent Application Publication No. 20040009530 and U.S. Patent No. 7,501,121, which are incorporated herein by reference.

[0305] In embodiments, a scaffold domain may be selected based on, for example, one or more of the following criteria: (1) amino acid sequence, (2) sequence of several homologous domains, (3) three-dimensional structure, and / or (4) stability data over a range of pH, temperature, salt, organic solvent, and oxidant concentration. In embodiments, the scaffold domain is a small, stable protein domain, e.g., a protein of less than 100, 70, 50, 40, or 30 amino acids. The domain may contain one or more disulfide bonds or may chelate a metal, e.g., zinc.

[0306] Antibody-Based Fusions A variety of formats can be generated that contain additional binding entities attached to the N- or C-terminus of the antibody. These fusions with single chain or disulfide-stabilized Fv or Fab result in the generation of tetravalent molecules with bivalent binding specificity for each antigen. The combination of scFv and scFab with IgG allows the production of molecules that can recognize three or more different antigens.

[0307] Antibody-Fab fusion An antibody-Fab fusion is a bispecific antibody that contains a traditional antibody against a first target and a Fab against a second target fused to the C-terminus of the antibody heavy chain. Generally, the antibody and Fab have a common light chain. Antibody fusions can be produced by (1) manipulating the DNA sequence of the target fusion and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. As described by Coloma, J et al. (1997) Nature Biotech 15:159, it appears that antibody-scFv fusions may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv.

[0308] Antibody-scFv fusion Antibody-scFv fusions are bispecific antibodies that contain a traditional antibody and a scFv of unique specificity fused to the C-terminus of the antibody heavy chain. The scFv can be fused to the C-terminus through the heavy chain of the scFv directly or through a linker peptide. Antibody fusions can be produced by (1) manipulating the DNA sequence of the target fusion and (2) transfecting the target DNA into a suitable host cell to express the fusion protein. As described by Coloma, J et al. (1997) Nature Biotech 15:159, it appears that antibody-scFv fusions may be linked by a (Gly)-Ser linker between the C-terminus of the CH3 domain and the N-terminus of the scFv.

[0309] Variable Domain Immunoglobulin DVD A related format is the dual variable domain immunoglobulin (DVD), which consists of a VH and a VL domain of a second specificity positioned N-terminal to the V domain by a shorter linker sequence.

[0310] Other exemplary multispecific antibody formats include, for example, those described in U.S. Patent Application Publication No. 20160114057A1, U.S. Patent Application Publication No. 20130243775A1, U.S. Patent Application Publication No. 20140051833, U.S. Patent Application Publication No. 20130022601, U.S. Patent Application Publication No. 20150017187A1, U.S. Patent Application Publication No. 20120201746A1, U.S. Patent Application Publication No. 20150133638A1, U.S. Patent Application Publication No. 20130266568A1, U.S. Patent Application Publication No. 20160145340A1, WO2015127158A1, U.S. Patent Application Publication No. 20150203591A1, U.S. Patent Application Publication No. 20140322221A1, U.S. Patent Application Publication No. 20130303396A1, U.S. Patent Application Publication No. 20110293613, U.S. Patent Application Publication No. 20130017200A1, U.S. Patent Application Publication No. 20160102135A1, WO2015197598A2, WO2015197582A1, U.S. Patent No. 9359437, U.S. Patent Application Publication No. 20150018529, WO2016115274A1, WO2016087416A1, U.S. Patent Application Publication No. 20080069820A1, Exemplary multispecific molecules utilizing full-length antibody-Fab / scFab formats include those described in the following: U.S. Patent No. 9,145,588B, U.S. Patent No. 7,919,257, and U.S. Patent Application Publication No. 20150232560A1. Exemplary multispecific molecules utilizing full-length antibody-Fab / scFab formats include those described in the following: U.S. Patent No. 9,382,323B2, U.S. Patent Application Publication No. 20140072581A1, U.S. Patent Application Publication No. 20140308285A1, U.S. Patent Application Publication No. 20130165638A1, U.S. Patent Application Publication No. 20130267686A1, U.S. Patent Application Publication No. 20140377269A1, U.S. Patent No. 7,741,446B2, and WO1995009917A1. Exemplary multispecific molecules utilizing the domain swapping format include those described in the following: US Patent Application Publication No. 20150315296A1, WO2016087650A1, US Patent Application Publication No. 20160075785A1, WO2016016299A1, US Patent Application Publication No. 20160130347A1, US Patent Application Publication No. 20150166670, U.S. Patent No. 8703132B2, US Patent Application Publication No. 20100316645, U.S. Patent No. 8227577B2, US Patent Application Publication No. 20130078249.

[0311] Fc-containing entities (mini-antibodies) Fc-containing entities, also known as mini-antibodies, can be generated by fusing scFv to the C-terminus of the constant heavy region domain 3 (CH3-scFv) and / or hinge region of an antibody with different specificity (scFv-hinge-Fc). Trivalent entities can also be made with disulfide-stabilized variable domains (without a peptide linker) fused to the C-terminus of the CH3 domain of an IgG.

[0312] Fc-containing multispecific molecules In some embodiments, the multispecific molecules disclosed herein comprise an immunoglobulin constant region (e.g., an Fc region). Exemplary Fc regions can be selected from the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4, more particularly, the heavy chain constant regions of human IgG1, IgG2, IgG3, or IgG4.

[0313] In some embodiments, the immunoglobulin chain constant region (e.g., Fc region) is altered, e.g., mutated, to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function.

[0314] In other embodiments, the interface of the first and second immunoglobulin chain constant regions (e.g., first and second Fc regions) is altered, e.g., mutated, to increase or decrease dimerization, e.g., compared to an unengineered interface, e.g., a naturally occurring interface. For example, dimerization of the immunoglobulin chain constant regions (e.g., Fc regions) can be enhanced by providing one or more of paired holes and protrusions ("knobs-in-holes"), electrostatic interactions, or strand exchange at the Fc interface of the first and second Fc regions, thereby forming, e.g., a higher ratio of heteromultimers:homomultimers compared to the unengineered interface.

[0315] In some embodiments, the multispecific molecule comprises paired amino acid substitutions, e.g., at positions selected from one or more of 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, of the Fc region of human IgG1. For example, the immunoglobulin chain constant region (e.g., Fc region) can comprise paired amino acid substitutions selected from T366S, L368A, or Y407V (e.g., corresponding to a pore or hole), and T366W (e.g., corresponding to a protuberance or knob).

[0316] In other embodiments, the multifunctional molecule comprises a half-life extender, for example, human serum albumin or an antibody molecule against human serum albumin. Heterodimerized antibody molecules and methods of production Various methods of producing multispecific antibodies have been disclosed to address the problem of incorrect heavy chain pairing. Exemplary methods are described below. Exemplary multispecific antibody formats and methods of making said multispecific antibodies are also disclosed, for example, in Speiss et al., Molecular Immunology 67 (2015) 95-106, and Klein et al., mAb 4:6, 653-663, November / December 2012 (the contents of each of which are hereby incorporated by reference herein).

[0317] Heterodimerized bispecific antibodies are based on the natural IgG structure, where the two binding arms recognize different antigens. IgG-derived formats that allow defined monovalent (and simultaneous) antigen binding are generated by forced heavy chain heterodimerization combined with techniques that minimize light chain mispairing (e.g., common light chains). Forced heavy chain heterodimerization can be obtained, for example, using knobs-in-holes or strand-exchange engineered domains (SEEDs).

[0318] Knob-in-Hole Knobs-in-holes, as described in U.S. Patent No. 5,731,116, U.S. Patent No. 7,476,724, and Ridgway, J. et al. (1996) Prot. Engineering 9(7):617-621, generally involve (1) mutating the CH3 domain of one or both antibodies to promote heterodimerization, and (2) combining the mutated antibodies under conditions that promote heterodimerization. The "knobs" or "protrusions" are typically created by replacing small amino acids in the parent antibody with larger ones (e.g., T366Y or T366W), and the "holes" or "pores" are created by replacing larger residues in the parent antibody with smaller ones (e.g., Y407T, T366S, L368A, and / or Y407V).

[0319] For bispecific antibodies that include an Fc domain, the introduction of specific mutations into the constant region of the heavy chain to promote correct heterodimerization of the Fc portion can be utilized. Some such techniques are reviewed in Klein et al. (mAb (2012) 4:6, pp. 1-11), the contents of which are hereby incorporated by reference in their entirety. These techniques include the "knob-into-hole" (KiH) approach, which involves the introduction of a bulky residue into one of the CH3 domains of one of the antibody heavy chains. This bulky residue fits into a complementary "hole" in the other CH3 domain of the paired heavy chain, thereby promoting correct pairing of the heavy chains (see, e.g., U.S. Pat. No. 7,642,228).

[0320] Exemplary KiH mutations include S354C, T366W in the "knob" heavy chain and Y349C, T366S, L368A, Y407V in the "hole" heavy chain. Other exemplary KiH mutations, along with additional optional stabilizing Fc cysteine ​​mutations, are provided in Table 1.

[0321] [Table 7]

[0322] Other Fc mutations were provided by Igawa and Tsunoda, who identified three negatively charged residues in the CH3 domain of one chain that pair with three positively charged residues in the CH3 domain of the other chain. These specific pairs of charged residues are E356-K439, E357-K370, D399-K409, and vice versa. By introducing at least two of the following mutations in chain B: K370E, K409D, K439E, as well as three in chain A: E356K, E357K and D399K, alone or in combination with the newly identified disulfide bridges, they could favor highly efficient heterodimerization while simultaneously suppressing homodimerization (Martens T et al., "A novel one-armed antic- Met antibody inhibits glioblastoma growth in vivo." Clin Cancer Res 2006;12:6144-52; PMID:17062691). Xencor defined 41 variant pairs based on a combination of structural calculations and sequence information, which were then screened for maximum heterodimerization, defining the combination S364H, F405A (HA) on chain A and Y349T, T394F (TF) on chain B (Moore GL et al., "A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens." MAbs 2011;3:546-57; PMID:22123055).

[0323] Other exemplary Fc mutations to promote heterodimerization of multispecific antibodies include those described in the following references, the contents of each of which are hereby incorporated by reference: WO2016071377A1, U.S. Patent Application Publication No. 20140079689A1, U.S. Patent Application Publication No. 20160194389A1, U.S. Patent Application Publication No. 20160257763, WO2016071376A2, WO2015107026A1, WO2015107025A1, WO2015107015A1, U.S. Patent Application Publication No. 20150353636A1, U.S. Patent Application Publication No. 20150403636A1, U.S. Patent Application Publication No. 20150 ... No. 20140199294A1, U.S. Patent Application Publication No. 7750128B2, U.S. Patent Application Publication No. 20160229915A1, U.S. Patent Application Publication No. 20150344570A1, U.S. Patent Application Publication No. 8003774A1, U.S. Patent Application Publication No. 20150337049A1, U.S. Patent Application Publication No. 20150175707A1, U.S. Patent Application Publication No. 20140242075A1, U.S. Patent Application Publication No. 20130195849A1, U.S. Patent Application Publication No. 20120149876A1, U.S. Patent Application Publication No. 20140200331A1, U.S. Patent Application Publication No. 9309311B2, U.S. Patent No. 8,586,713, U.S. Patent Application Publication No. 20140037621A1, U.S. Patent Application Publication No. 20130178605A1, U.S. Patent Application Publication No. 20140363426A1, U.S. Patent Application Publication No. 20140051835A1, and U.S. Patent Application Publication No. 20110054151A1.

[0324] Stabilizing cysteine ​​mutations have also been used in combination with KiH and other Fc heterodimerization-promoting variants (see, e.g., U.S. Patent No. 7,183,076). Other exemplary cysteine ​​modifications include those disclosed, for example, in U.S. Patent Application Publication No. 20140348839A1, U.S. Patent No. 7,855,275B2, and U.S. Patent No. 9,000,130B2.

[0325] Strand exchange engineering domain (SEED) Heterodimeric Fc platforms are known that support the design of bispecific and asymmetric fusion proteins by engineering strand exchange engineered domain (SEED) C(H)3 heterodimers. These derivatives of human IgG and IgA C(H)3 domains create complementary human SEED C(H)3 heterodimers composed of alternating segments of human IgA and IgG C(H)3 sequences. The resulting pairs of SEED C(H)3 domains preferentially associate to form heterodimers when expressed in mammalian cells. SEED body (Sb) fusion proteins consist of [IgG1 hinge]-C(H)2-[SEED C(H)3], which may be genetically linked to one or more fusion partners (see, e.g., Davis JH et al., "SEEDbodies: fusion proteins based on strand exchange engineered domain (SEED) CH3 heterodimers in and Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies." Protein Eng Des Sel 2010;23:195-202; PMID:20299542 and U.S. Pat. No. 8,871,912, the contents of each of which are hereby incorporated by reference.

[0326] Duo Body "Duobody" technology for producing bispecific antibodies with correct heavy chain pairing is known. Duobody technology involves three basic steps to generate bispecific human IgG1 antibodies that are stable in a post-production exchange reaction. In the first step, two IgG1s, each containing a single matched mutation in the third constant (CH3) domain, are produced separately using a standard mammalian recombinant cell system. These IgG1 antibodies are then purified according to standard methods for recovery and purification. After production and purification (post-production), the two antibodies are recombined under controlled laboratory conditions to result in a bispecific antibody product with very high yields (typically >95%) (see, for example, Labrijn et al., PNAS 2013;110(13):5145-5150 and Labrijn et al., Nature Protocols 2014;9(10):2450-63, the contents of each of which are hereby incorporated by reference).

[0327] Electrostatic interactions Methods for making multispecific antibodies using CH3 amino acid changes with charged amino acids such that homodimer formation is electrostatically disfavored have been disclosed. EP1870459 and WO2009089004 describe other strategies for favoring heterodimer formation upon co-expression of different antibody domains in a host cell. In these methods, the heavy chain constant domain 3 (CH3), one or more residues making up the CH3-CH3 interface in both CH3 domains, are replaced with charged amino acids such that homodimer formation is electrostatically disfavored and heterodimerization is electrostatically favored. Using electrostatic interactions, Additional methods for making multispecific molecules using ribozymes are described in references including U.S. Patent Application Publication No. 20100015133, U.S. Patent No. 8,592,562 B2, U.S. Patent No. 9,200,060 B2, U.S. Patent Application Publication No. 20140154254 A1, and U.S. Patent No. 9,358,286 A1, the contents of each of which are hereby incorporated by reference.

[0328] Common light chain Light chain mispairing needs to be avoided to generate homogeneous preparations of bispecific IgG. One way to achieve this is through the use of the common light chain principle, i.e., combining two binders that share one light chain but still have separate specificities. An exemplary method of enhancing the formation of the desired bispecific antibody from a mixture of monomers is by providing a common variable light chain to interact with each of the heteromeric variable heavy chain regions of the bispecific antibody. Compositions of bispecific antibodies with a common light chain and methods for their production are disclosed, for example, in U.S. Pat. No. 7,183,076 B2, U.S. Pat. App. Pub. No. 20110177073 A1, EP2847231 A1, WO2016079081 A1, and EP3055329 A1, the contents of each of which are hereby incorporated by reference herein.

[0329] CrossMab Another option to reduce light chain mispairing is the CrossMab technology, which avoids non-specific L chain mispairing by swapping the CH1 and CL domains in one half of the Fab of a bispecific antibody. Such crossover variants retain the binding specificity and affinity, but make the two arms different so that L chain mispairing is prevented. (As reviewed in Klein et al., supra) CrossMab technology involves domain swapping between heavy and light chains to promote the formation of correct pairings. Briefly, a two-step modification process is applied to construct a bispecific IgG-like CrossMab antibody that can bind to two antigens by using two distinct light-heavy chain pairs. First, a dimerization interface is engineered into the C-terminus of each heavy chain using a heterodimerization approach, e.g., knob-into-hole (KiH) technology, to ensure that only heterodimers of two distinct heavy chains from one antibody (e.g., antibody A) and a second antibody (e.g., antibody B) are efficiently formed. Next, the constant heavy chain 1 (CH1) and constant light chain (CL) domains of one antibody are exchanged (Antibody A), while keeping the variable heavy chain (VH) and variable light chain (VL) domains consistent. The exchange of CH1 and CL domains ensured that only the desired bispecific CrossMab was efficiently formed, since the modified antibody (Antibody A) light chain only dimerized efficiently with the modified antibody (Antibody A) heavy chain, and the unmodified antibody (Antibody B) light chain only dimerized efficiently with the unmodified antibody (Antibody B) heavy chain (see, e.g., Cain, C., SciBX 4(28);doi:10.1038 / scibx.2011.783, the contents of which are hereby incorporated by reference).

[0330] Common heavy chain An exemplary method of enhancing the formation of a desired bispecific antibody from a mixture of monomers is by providing a common variable heavy chain to interact with each of the heteromeric variable light chain regions of the bispecific antibody. Compositions of bispecific antibodies having a common heavy chain and methods for their production are disclosed, for example, in U.S. Patent Application Publication No. 20120184716, U.S. Patent Application Publication No. 20130317200, and U.S. Patent Application Publication No. 20160264685A1, the contents of each of which are hereby incorporated by reference herein.

[0331] Amino acid modifications Alternative compositions and methods for producing multispecific antibodies with correct light chain pairing include various amino acid modifications. For example, Zymeworks has developed a method for modifying the amino acid sequence between the light and heavy chains. Described herein are heterodimers that have one or more amino acid modifications in the CH1 and / or CL domains, one or more amino acid modifications in the VH and / or VL domains, or a combination thereof, that are part of the interface and create preferential pairing of each heavy chain with a desired light chain, such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains over the other (see, for example, WO2015181805). Other exemplary methods are described in WO2016026943 (Argen-X), US Patent Application Publication No. 20150211001, US Patent Application Publication No. 20140072581A1, US Patent Application Publication No. 20160039947A1, and US Patent Application Publication No. 20150368352.

[0332] Lambda / Kappa format Multispecific molecules (e.g., multispecific antibody molecules) comprising lambda and kappa light chain polypeptides can be used to allow heterodimerization. Methods for producing bispecific antibody molecules comprising lambda and kappa light chain polypeptides are disclosed in PCT / US17 / 53053, filed September 22, 2017, which is hereby incorporated by reference in its entirety.

[0333] In embodiments, a multispecific molecule comprises a multispecific antibody molecule, e.g., an antibody molecule that comprises two binding specificities, e.g., a bispecific antibody molecule. A multispecific antibody molecule comprises: Lambda light chain polypeptide 1 (LLCP1) specific for a first epitope; heavy chain polypeptide 1 (HCP1) specific for a first epitope; a kappa light chain polypeptide 2 (KLCP2) specific for a second epitope, and Heavy chain polypeptide 2 (HCP2) specific for a second epitope Includes.

[0334] "Lambda light chain polypeptide 1 (LLCP1)", as that term is used herein, refers to a polypeptide that includes sufficient light chain (LC) sequence that, when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with HCP1. In one embodiment, it includes all or a fragment of the CH1 region. In one embodiment, LLCP1 includes LC-CDR1, LC-CDR2, LC-CDR3, FR1, FR2, FR3, FR4, and CH1, or sequences therefrom sufficient to mediate specific binding of its epitope and complex with HCP1. LLCP1, together with its HCP1, provides specificity for a first epitope (KLCP2, together with its HCP2, provides specificity for a second epitope). As described elsewhere herein, LLCP1 has a higher affinity for HCP1 than for HCP2.

[0335] "Kappa light chain polypeptide 2 (KLCP2)", as that term is used herein, refers to a polypeptide that includes sufficient light chain (LC) sequence that, when combined with a cognate heavy chain variable region, can mediate specific binding to its epitope and complex with HCP2. In one embodiment, it includes all or a fragment of the CH1 region. In one embodiment, KLCP2 includes LC-CDR1, LC-CDR2, LC-CDR3, FR1, FR2, FR3, FR4, and CH1, or sufficient sequences therefrom to mediate specific binding of its epitope and complex with HCP2. KLCP2, together with its HCP2, provides specificity for a second epitope (LLCP1, together with its HCP1, provides specificity for a first epitope).

[0336] "Heavy chain polypeptide 1 (HCP1)," as that term is used herein, when combined with its cognate LLCP1, mediates specific binding to its epitope; It refers to a polypeptide that includes sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, that can complex with HCP1. In one embodiment, it includes all or a fragment of the CH1 region. In one embodiment, it includes all or a fragment of the CH2 and / or CH3 region. In one embodiment, HCP1 includes HC-CDR1, HC-CDR2, HC-CDR3, FR1, FR2, FR3, FR4, CH1, CH2, and CH3, or sequences therefrom sufficient to (i) mediate specific binding of its epitope, complex with LLCP1, (ii) preferentially complex with LLCP1 as opposed to KLCP2 as described herein, and (iii) preferentially complex with HCP2 as opposed to another molecule of HCP1 as described herein. HCP1, together with its LLCP1, provides specificity for a first epitope (KLCP2, together with its HCP2, provides specificity for a second epitope).

[0337] "Heavy chain polypeptide 2 (HCP2)", as that term is used herein, refers to a polypeptide that includes sufficient heavy chain (HC) sequence, e.g., HC variable region sequence, that when combined with the cognate LLCP1, can mediate specific binding to its epitope and complex with HCP1. In one embodiment, it includes all or a fragment of the CH1 region. In one embodiment, it includes all or a fragment of the CH2 and / or CH3 regions. In one embodiment, HCP1 includes HC-CDR1, HC-CDR2, HC-CDR3, FR1, FR2, FR3, FR4, CH1, CH2, and CH3, or sequences therefrom sufficient to (i) mediate specific binding of its epitope and complex with KLCP2, (ii) preferentially complex to KLCP2 as opposed to LLCP1 as described herein, and (iii) preferentially complex to HCP1 as opposed to another molecule of HCP2 as described herein. HCP2, together with its KLCP2, provides specificity for the second epitope (LLCP1, together with its HCP1, provides specificity for the first epitope).

[0338] In some embodiments of the multispecific antibody molecules disclosed herein, LLCP1 has a higher affinity for HCP1 than for HCP2, and / or KLCP2 has a higher affinity for HCP2 than for HCP1.

[0339] In embodiments, the affinity of LLCP1 for HCP1 is sufficiently greater than its affinity for HCP2, such that under preselected conditions, e.g., in an aqueous buffer, e.g., pH 7, in saline, e.g., pH 7, or under physiological conditions, at least 75, 80, 90, 95, 98, 99, 99.5, or 99.9% of the multispecific antibody molecule has LLCP1 complexed or associated with HCP1.

[0340] In some embodiments of the multispecific antibody molecules disclosed herein, HCP1 has a higher affinity for HCP2 than for a second molecule of HCP1, and / or HCP2 has a higher affinity for HCP1 than for a second molecule of HCP2.

[0341] In embodiments, the affinity of HCP1 for HCP2 is sufficiently greater than its affinity for a second molecule, such that under preselected conditions, e.g., in an aqueous buffer, e.g., pH 7, in saline, e.g., pH 7, or under physiological conditions, at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9% of the multispecific antibody molecules have HCP1 complexed or associated with HCP2.

[0342] In another aspect, a method for making or producing a multispecific antibody molecule is disclosed herein. The method includes carrying out the steps of: (i) providing a first heavy chain polypeptide (e.g., a heavy chain polypeptide that includes one, two, three, or all of a first heavy chain variable region (first VH), a first CH1, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both); (ii) providing a second heavy chain polypeptide (e.g., a heavy chain polypeptide comprising one, two, three, or all of a second heavy chain variable region (second VH), a second CH1, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both); (iii) providing a lambda chain polypeptide (e.g., a lambda light chain variable region (VLλ), a lambda light chain constant chain (VLλ), or both) that preferentially associates with a first heavy chain polypeptide (e.g., a first VH); and (iv) providing a kappa chain polypeptide (e.g., a lambda light chain variable region (VLκ), a lambda light chain constant chain (VLκ), or both) that preferentially associates with a second heavy chain polypeptide (e.g., a second VH). Includes.

[0343] In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization. In embodiments, (i)-(iv) (e.g., nucleic acids encoding (i)-(iv)) are introduced into a single cell, e.g., a single mammalian cell, e.g., a CHO cell. In embodiments, (i)-(iv) are expressed in the cell.

[0344] In embodiments, (i)-(iv) (e.g., nucleic acids encoding (i)-(iv)) are introduced into different cells, e.g., different mammalian cells, e.g., two or more CHO cells. In embodiments, (i)-(iv) are expressed in the cells.

[0345] In one embodiment, the method further comprises purifying the cell-expressed antibody molecules, e.g., using lambda and / or kappa specific purification, e.g., affinity chromatography.

[0346] In an embodiment, the method further comprises evaluating the cell-expressed multispecific antibody molecule. For example, the purified cell-expressed multispecific antibody molecule can be analyzed by techniques known in the art, including mass spectrometry. In one embodiment, the purified cell-expressed antibody molecule is cleaved, e.g., digested with papain to provide a Fab portion, and evaluated using mass spectrometry.

[0347] In embodiments, the methods produce high yields, e.g., at least 75%, 80, 90, 95, 98, 99 99.5 or 99.9%, of correctly paired kappa / lambda polyspecific, e.g., bispecific, antibody molecules.

[0348] In other embodiments, the multispecific, e.g., bispecific, antibody molecule comprises: (i) a first heavy chain polypeptide (HCP1) (e.g., a heavy chain polypeptide that includes one, two, three, or all of a first heavy chain variable region (first VH), a first CH1, a first heavy chain constant region (e.g., a first CH2, a first CH3, or both)), e.g., HCP1, that binds a first epitope; (ii) a second heavy chain polypeptide (HCP2) (e.g., a heavy chain polypeptide that includes one, two, three, or all of a second heavy chain variable region (second VH), a second CH1, a second heavy chain constant region (e.g., a second CH2, a second CH3, or both)), e.g., a HCP2 that binds a second epitope; (iii) a lambda light chain polypeptide (LLCP1) (e.g., a lambda light chain variable region (VL1), a lambda light chain constant region (LLCP2)) that preferentially associates with a first heavy chain polypeptide (e.g., a first VH) common chain (VL1), or both), e.g., LLCP1, which binds to a first epitope, and (iv) a kappa light chain polypeptide (KLCP2) (e.g., a lambda light chain variable region (VLk), a lambda light chain constant chain (VLk), or both) that preferentially associates with a second heavy chain polypeptide (e.g., a second VH), e.g., binds a second epitope, KLCP2 Includes.

[0349] In embodiments, the first and second heavy chain polypeptides form an Fc interface that enhances heterodimerization. In embodiments, the multispecific antibody molecule has a first binding specificity that comprises an Fc constant, a hybrid VLl-CLl heterodimerized to a first heavy chain variable region connected to a CH2-CH3 domain (with a knob modification), and a second binding specificity that comprises an Fc constant, a hybrid VLk-CLk heterodimerized to a second heavy chain variable region connected to a CH2-CH3 domain (with a hole modification).

[0350] Linker The multispecific or multifunctional molecules disclosed herein may further comprise a linker, e.g., a linker in one or more of between the antigen binding domain and the cytokine molecule, between the antigen binding domain and the immune cell engager, between the antigen binding domain and the stromal modifying moiety, between the cytokine molecule and the immune cell engager, between the cytokine molecule and the stromal modifying moiety, between the immune cell engager and the stromal modifying moiety, between the antigen binding domain and the immunoglobulin chain constant region, between the cytokine molecule and the immunoglobulin chain constant region, between the immune cell engager and the immunoglobulin chain constant region, or between the stromal modifying moiety and the immunoglobulin chain constant region. In embodiments, the linker is selected from a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker, or a combination thereof.

[0351] In one embodiment, the multispecific molecule may include one, two, three, or four linkers, e.g., peptide linkers. In one embodiment, the peptide linker includes Gly and Ser. In some embodiments, the peptide linker is selected from GGGGS (SEQ ID NO: 42); GGGGSGGGGS (SEQ ID NO: 43); GGGGSGGGGSGGGGGS (SEQ ID NO: 44); and DVPSGPGGGGGSGGGGS (SEQ ID NO: 45). In some embodiments, the peptide linker is a linker of the A(EAAAK)nA (SEQ ID NO: 6154) family (e.g., as described in Protein Eng. (2001) 14 (8): 529-532). These are rigid helical linkers with n ranging from 2 to 5. In some embodiments, the peptide linker is selected from AEAAAKEAAAKAAA (SEQ ID NO: 75); AEAAAKEAAAKEAAAKAAA (SEQ ID NO: 76); AEAAAKEAAAKEAAAKEAAAKAAA (SEQ ID NO: 77); and AEAAAKEAAAKEAAAKEAAAKEAAAKAAA (SEQ ID NO: 78).

[0352] targeting part In one embodiment, the anti-NKp30 antibody molecule further comprises a second antigen-binding moiety, e.g., a tumor targeting moiety, that binds to a cancer antigen, e.g., a tumor antigen or a stromal antigen. In some embodiments, the cancer antigen is, e.g., a mammalian, e.g., human, cancer antigen. In other embodiments, the antibody molecule further comprises a second binding moiety that binds to an immune cell antigen, e.g., a mammalian, e.g., human, immune cell antigen. In other embodiments, the antibody molecule further comprises a second binding moiety that binds to a viral antigen. For example, the antibody molecule specifically binds to an epitope, e.g., a linear or conformational epitope, on a cancer antigen, an immune cell antigen.

[0353] In some embodiments, the multispecific (e.g., bi-, tri-, tetraspecific) molecule is engineered to contain one or more tumor-specific targeting moieties, e.g., directing the molecule to tumor cells. In certain embodiments, the multispecific molecules disclosed herein include a tumor-targeting moiety. The tumor targeting moiety can be selected from an antibody molecule (e.g., an antigen-binding domain described herein), a receptor or receptor fragment, or a ligand or ligand fragment, or a combination thereof. In some embodiments, the tumor targeting moiety associates with, e.g., binds to, a tumor cell (e.g., a molecule, e.g., an antigen, present on the surface of a tumor cell). In certain embodiments, the tumor targeting moiety targets, e.g., directs, e.g., a multispecific molecule disclosed herein, to a cancer (e.g., a cancer or tumor cell). In some embodiments, the cancer is selected from a hematological cancer, a solid cancer, a metastatic cancer, or a combination thereof.

[0354] In some embodiments, the multispecific molecule, e.g., tumor targeting moiety, binds to a solid tumor antigen or stromal antigen. The solid tumor antigen or stromal antigen can be present on a solid tumor, or on a metastatic lesion thereof. In some embodiments, the solid tumor is selected from one or more of pancreatic cancer (e.g., pancreatic adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g., small cell carcinoma or non-small cell lung carcinoma), skin cancer, ovarian cancer, or liver cancer. In one embodiment, the solid tumor is a fibrotic or desmoplastic solid tumor. For example, the solid tumor antigen or stromal antigen can be present on a tumor, e.g., a class of tumor that typically has one or more of limited tumor perfusion, vascular compression, or fibrotic tumor stroma.

[0355] In certain embodiments, the solid tumor antigen is PDL1, CD47, mesothelin, ganglioside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PMSA), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), Ron kinase, c-Met, immature laminin receptor, TAG-72, BING-4, calcium activated chloride channel 2, cyclin-B1, 9D7, Ep-CAM, E phA3, Her2 / neu, telomerase, SAP-1, survivin, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, Gp100 / pmel17, tyrosinase, TRP-1 / -2, MC1R, β-catenin, BRCA1 / 2, CDK4, CML66, fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, MUC-1, CA-125 , BAGE, GAGE, NY-ESO-1, β-catenin, CDK4, CDC27, CD47, α-actinin-4, TRP1 / gp75, TRP2, gp100, Melan-A / MART1, ganglioside, WT1, EphA3, epidermal growth factor receptor (EGFR), CD20, MART-2, MART-1, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC , RUI1, RUI2, SAGE, TRG, TRP1, TSTA, folate receptor alpha, L1-CAM, CAIX, EGFRvIII, gpA33, GD3, GM2, VEGFR, integrins (integrin alpha V beta 3, integrin alpha 5 beta 1), carbohydrate (Le), IGF1R, EPHA3, TRAILR1, TRAILR2, or RANKL. In some embodiments, the solid tumor antigen is selected from PDL1, mesothelin, CD47, GD2, PMSA, PSCA, CEA, Ron kinase, or c-Met. Exemplary amino acid and nucleotide sequences of tumor targeting moieties are disclosed in WO2017 / 165464, which is incorporated herein by reference, see, e.g., pages 102-108, 172-290.

[0356] In some embodiments, the anti-NKp30 antibody molecule (e.g., a multispecific antibody molecule) further comprises a targeting moiety, e.g., a binding specificity, that binds to an antigen present on the surface of an autoreactive T cell, e.g., an autoreactive T cell associated with an inflammatory or autoimmune disorder.

[0357] In some embodiments, the anti-NKp30 antibody molecule (e.g., a multispecific antibody molecule) further comprises a targeting moiety, e.g., a binding specificity, that binds to an infected cell, e.g., a virally infected cell.

[0358] T Cell Engager In other embodiments, the anti-NKp30 antibody molecule (e.g., a multispecific antibody molecule) further comprises one or more T cell engagers that mediate binding to and / or activation of T cells. Thus, in some embodiments, the T cell engager is selected from an antigen-binding domain or ligand that binds (e.g., in some embodiments, activates) one or more of CD3, TCRα, TCRβ, TCRγ, TCRζ, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226. In other embodiments, the T cell engager is selected from an antigen-binding domain or ligand that binds and does not activate one or more of CD3, TCR alpha, TCR beta, TCR gamma, TCR zeta, ICOS, CD28, CD27, HVEM, LIGHT, CD40, 4-1BB, OX40, DR3, GITR, CD30, TIM1, SLAM, CD2, or CD226.

[0359] Exemplary T cell engagers are disclosed in WO 2017 / 165464, which is incorporated herein by reference. Cytokine molecules In other embodiments, the anti-NKp30 antibody molecule (e.g., multispecific antibody molecule) further comprises one or more cytokine molecules, e.g., immunomodulatory (e.g., pro-inflammatory) cytokines and variants, e.g., functional variants thereof. Thus, in some embodiments, the cytokine molecule is an interleukin or a variant, e.g., functional variant thereof. In some embodiments, the interleukin is a pro-inflammatory interleukin. In some embodiments, the interleukin is selected from interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), interleukin-7 (IL-7), or interferon gamma. In some embodiments, the cytokine molecule is a pro-inflammatory cytokine. In certain embodiments, the cytokine is a single chain cytokine. In certain embodiments, the cytokine is a multi-chain cytokine (e.g., the cytokine comprises two or more (e.g., two) polypeptide chains. An exemplary multi-chain cytokine is IL-12.

[0360] Examples of useful cytokines include, but are not limited to, GM-CSF, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-21, IFN-α, IFN-β, IFN-γ, MIP-1α, MIP-1β, TGF-β, TNF-α, and TNFβ. In one embodiment, the cytokine of the multispecific or multifunctional polypeptide is a cytokine selected from the group of GM-CSF, IL-2, IL-7, IL-8, IL-10, IL-12, IL-15, IL-21, IFN-α, IFN-γ, MIP-1α, MIP-1β, and TGF-β. In one embodiment, the cytokine of the multispecific or multifunctional polypeptide is a cytokine selected from the group of IL-2, IL-7, IL-10, IL-12, IL-15, IFN-α, and IFN-γ. In certain embodiments, the cytokine is mutated to remove N- and / or O-glycosylation sites. Elimination of glycosylation increases the homogeneity of the product that can be obtained in recombinant production.

[0361] In one embodiment, the cytokine of the multispecific or multifunctional polypeptide is IL-2. In a particular embodiment, the IL-2 cytokine inhibits the proliferation, activity, and proliferation of activated T lymphocyte cells. The IL-2 cytokine can induce one or more of the following cellular responses selected from the group consisting of differentiation of activated T lymphocyte cells, cytotoxic T cell (CTL) activity, proliferation of activated B cells, differentiation of activated B cells, proliferation of natural killer (NK) cells, differentiation of NK cells, cytokine secretion by activated T cells or NK cells, and NK / lymphocyte-activated killer (LAK) antitumor cytotoxicity. In another specific embodiment, the IL-2 cytokine is a mutant IL-2 cytokine with reduced binding affinity to the alpha-subunit of the IL-2 receptor. The alpha-subunit (also known as CD25) together with the beta and gamma-subunits (known as CD122 and CD132, respectively) form a heterotrimeric high-affinity IL-2 receptor, while a dimeric receptor consisting only of the beta- and gamma-subunits is referred to as the intermediate-affinity IL-2 receptor. As described in PCT Patent Application No. PCT / EP2012 / 051991 (hereby incorporated by reference in its entirety), mutant IL-2 polypeptides with reduced binding to the alpha-subunit of the IL-2 receptor have a reduced ability to induce IL-2 signaling in regulatory T cells, induce less activation-induced cell death (AICD) in T cells, and have a reduced toxicity profile in vivo compared to wild-type IL-2 polypeptides. The use of such cytokines with reduced toxicity is particularly advantageous in multispecific or multifunctional polypeptides according to the invention that have a long serum half-life due to the presence of an Fc domain. In one embodiment, the mutant IL-2 cytokine of the multispecific or multifunctional polypeptide according to the invention comprises at least one amino acid mutation that reduces or eliminates the affinity of the mutant IL-2 cytokine for the alpha-subunit of the IL-2 receptor (CD25) but preserves the affinity of the mutant IL-2 cytokine for the intermediate affinity IL-2 receptor (consisting of the β and γ subunits of the IL-2 receptor) compared to the non-mutated IL-2 cytokine. In one embodiment, the one or more amino acid mutations are amino acid substitutions.In a particular embodiment, the mutant IL-2 cytokine comprises one, two or three amino acid substitutions at one, two or three positions selected from positions corresponding to residues 42, 45 and 72 of human IL-2. In a more particular embodiment, the mutant IL-2 cytokine comprises three amino acid substitutions at positions corresponding to residues 42, 45 and 72 of human IL-2. In an even more particular embodiment, the mutant IL-2 cytokine is human IL-2 comprising the amino acid substitutions F42A, Y45A and L72G. In one embodiment, the mutant IL-2 cytokine additionally comprises an amino acid mutation at a position corresponding to position 3 of human IL-2, which eliminates the O-glycosylation site of IL-2. In particular, said additional amino acid mutation is an amino acid substitution replacing a threonine residue with an alanine residue. A particular mutant IL-2 cytokine useful in the present invention comprises four amino acid substitutions at positions corresponding to residues 3, 42, 45 and 72 of human IL-2. Specific amino acid substitutions are T3A, F42A, Y45A and L72G. As demonstrated in PCT patent application no. PCT / EP2012 / 051991 and the appended examples, the quadruple mutant IL-2 polypeptide (IL-2 qm) exhibits no detectable binding to CD25, exhibits a reduced ability to induce apoptosis in T cells, exhibits a reduced ability to induce IL-2 signaling in regulatory T cells (T.sub.reg cells), and exhibits a reduced toxicity profile in vivo. However, it retains the ability to activate IL-2 signaling in effector cells, induce the proliferation of effector cells, and produce IFN-γ as a secondary cytokine by NK cells.

[0362] The IL-2 or mutant IL-2 cytokine according to any of the above embodiments may contain additional mutations that provide further advantages, such as increased expression or stability. For example, the cysteine ​​at position 125 may be replaced with a neutral amino acid, such as alanine, to avoid the formation of IL-2 dimers by disulfide bridges. Thus, in certain embodiments, the IL-2 or mutant IL-2 cytokine of the multispecific or multifunctional polypeptide according to the invention may be replaced with a neutral amino acid, such as alanine, to avoid the formation of IL-2 dimers by disulfide bridges. or the mutant IL-2 cytokine comprises an additional amino acid mutation at a position corresponding to residue 125 of human IL-2. In one embodiment, said additional amino acid mutation is the amino acid substitution C125A.

[0363] Exemplary cytokine molecules are disclosed in WO2017 / 165464, which is incorporated by reference herein, see e.g., pages 108-118, 169-172. TGF-β inhibitors In other embodiments, the anti-NKp30 antibody molecule (e.g., multispecific antibody molecule) further comprises one or more modulators of TGF-β (e.g., a TGF-β inhibitor). In some embodiments, the TGF-β inhibitor binds to and inhibits TGF-β, e.g., reduces the activity of TGF-β. In some embodiments, the TGF-β inhibitor inhibits (e.g., reduces its activity) TGF-β1. In some embodiments, the TGF-β inhibitor inhibits (e.g., reduces its activity) TGF-β2. In some embodiments, the TGF-β inhibitor inhibits (e.g., reduces its activity) TGF-β3. In some embodiments, the TGF-β inhibitor inhibits (e.g., reduces the activity) TGF-β1 and TGF-β3. In some embodiments, the TGF-β inhibitor inhibits (e.g., reduces the activity) TGF-β1, TGF-β2, and TGF-β3.

[0364] In some embodiments, the TGF-β inhibitor comprises a portion of a TGF-β receptor (e.g., the extracellular domain of a TGF-β receptor) that can inhibit (e.g., reduce the activity of) TGF-β, or a functional fragment or variant thereof. In some embodiments, the TGF-β inhibitor comprises a TGFBR1 polypeptide (e.g., the extracellular domain of TGFBR1 or a functional variant thereof). In some embodiments, the TGF-β inhibitor comprises a TGFBR2 polypeptide (e.g., the extracellular domain of TGFBR2 or a functional variant thereof). In some embodiments, the TGF-β inhibitor comprises a TGFBR3 polypeptide (e.g., the extracellular domain of TGFBR3 or a functional variant thereof). In some embodiments, the TGF-β inhibitor comprises a TGFBR1 polypeptide (e.g., the extracellular domain of TGFBR1 or a functional variant thereof) and a TGFBR2 polypeptide (e.g., the extracellular domain of TGFBR2 or a functional variant thereof). In some embodiments, the TGF-β inhibitor comprises a TGFBR1 polypeptide (e.g., the extracellular domain of TGFBR1 or a functional variant thereof) and a TGFBR3 polypeptide (e.g., the extracellular domain of TGFBR3 or a functional variant thereof). In some embodiments, the TGF-β inhibitor comprises a TGFBR2 polypeptide (e.g., the extracellular domain of TGFBR2 or a functional variant thereof) and a TGFBR3 polypeptide (e.g., the extracellular domain of TGFBR3 or a functional variant thereof).

[0365] Exemplary TGF-β receptor polypeptides that can be used as TGF-β inhibitors are disclosed in US8993524, US9676863, US8658135, US20150056199, US20070184052, and WO2017037634, all of which are incorporated by reference in their entireties.

[0366] In some embodiments, the TGF-β inhibitor comprises the extracellular domain of TGFBR1 or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3095 or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3096 or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3097 or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3104, or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3105, or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto).

[0367] In some embodiments, the TGF-β inhibitor comprises the extracellular domain of TGFBR2 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3098 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3099 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3100 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3101, or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3102, or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3103, or a sequence substantially identical thereto (e.g., a sequence at least 80%, 85%, 90%, or 95% identical thereto).

[0368] In some embodiments, the TGF-β inhibitor comprises the extracellular domain of TGFBR3 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3106 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the extracellular domain of SEQ ID NO: 3107 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto). In some embodiments, the TGF-β inhibitor comprises the amino acid sequence of SEQ ID NO: 3108 or a sequence substantially identical thereto (e.g., at least 80%, 85%, 90%, or 95% identical thereto).

[0369] In some embodiments, the TGF-β inhibitor comprises only one TGF-β receptor extracellular domain. In some embodiments, the TGF-β inhibitor comprises two or more (e.g., two, three, four, five, or more) TGF-β receptor extracellular domains linked, e.g., via a linker.

[0370] [Table 8-1]

[0371] [Table 8-2]

[0372] [Table 8-3]

[0373] [Table 8-4]

[0374] [Table 8-5]

[0375] [Table 8-6]

[0376] [Table 8-7]

[0377] [Table 8-8]

[0378] [Table 8-9]

[0379] Stroma modification part In other embodiments, the anti-NKp30 antibody molecule (e.g., a multispecific antibody molecule) further comprises one or more stromal-modifying moieties. Stromal-modifying moieties described herein include moieties (e.g., proteins, e.g., enzymes) that can degrade components of the stroma, e.g., ECM components, e.g., glycosaminoglycans, e.g., hyaluronan (also known as hyaluronic acid or HA), chondroitin sulfate, chondroitin, dermatan sulfate, heparin sulfate, heparin, entactin, tenascin, aggrecan, and keratin sulfate; or extracellular proteins, e.g., collagen, laminin, elastin, fibrinogen, fibronectin, and vitronectin.

[0380] In some embodiments, the stromal modifying moiety is an enzyme. For example, the stromal modifying moiety can include, but is not limited to, hyaluronidase, collagenase, chondroitinase, matrix metalloproteinase (e.g., macrophage metalloelastase).

[0381] Exemplary amino acid and nucleotide sequences for stromal-modifying moieties are disclosed in WO2017 / 165464, which is incorporated by reference herein, see e.g., pages 131-136, 188-193.

[0382] nucleic acid Nucleic acids encoding the aforementioned antibody molecules, eg, multispecific or multifunctional molecules, are also disclosed.

[0383] In certain embodiments, the present invention relates to nucleic acids comprising nucleotide sequences encoding the heavy and light chain variable regions and CDRs or hypervariable loops of the antibody molecules described herein. For example, the invention features first and second nucleic acids encoding heavy and light chain variable regions, respectively, of an antibody molecule selected from one or more of the antibody molecules disclosed herein. The nucleic acids comprise a nucleotide sequence set forth in the tables herein, or a sequence substantially identical thereto (e.g., at least about 85%, 90%, 95%, 99% or more identical thereto, or a sequence that differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequence set forth in the tables herein).

[0384] In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having an amino acid sequence set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or having one or more substitutions, e.g., conservative substitutions). In other embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having an amino acid sequence set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or having one or more substitutions, e.g., conservative substitutions). In yet another embodiment, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having the amino acid sequences set out in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or having one or more substitutions, e.g., conservative substitutions).

[0385] In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a heavy chain variable region having a nucleotide sequence set forth in the tables herein, or a sequence substantially homologous thereto (e.g., at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions as described herein). In another embodiment, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, or three CDRs or hypervariable loops from a light chain variable region having a nucleotide sequence set forth in the tables herein, or a sequence substantially homologous thereto (e.g., at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions as described herein). In yet another embodiment, the nucleic acid may comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs or hypervariable loops from heavy and light chain variable regions having the nucleotide sequences set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto and / or capable of hybridizing under stringency conditions as described herein).

[0386] In certain embodiments, the nucleic acid may comprise a nucleotide sequence encoding a cytokine molecule, immune cell engager, or stromal-modifying moiety disclosed herein. In another aspect, the application features host cells and vectors that include the nucleic acids described herein. The nucleic acids can be present in a single vector or in separate vectors that are present in the same host cell or in separate host cells, as described in more detail herein below.

[0387] vector Additionally, nucleotides encoding the multispecific or multifunctional molecules described herein Provided herein is a vector comprising the sequence.In one embodiment, the vector comprises the nucleotide encoding the multispecific or multifunctional molecule described herein.In one embodiment, the vector comprises the nucleotide sequence described herein.Vector includes, but is not limited to, virus, plasmid, cosmid, lambda phage, or yeast artificial chromosome (YAC).

[0388] A number of vector systems can be used. For example, one class of vectors utilizes DNA elements derived from animal viruses, such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retrovirus (Rous sarcoma virus, MMTV, or MOMLV), or SV40 virus. Another class of vectors utilizes RNA elements derived from RNA viruses, such as Semliki Forest virus, Eastern equine encephalitis virus, and flaviviruses.

[0389] In addition, cells in which the DNA has been stably integrated into the chromosome can be selected by introducing one or more markers that allow the selection of transfected host cells. Markers can provide, for example, prototropy to auxotrophic hosts, biocide resistance (e.g., antibiotics), or resistance to heavy metals, such as copper. The selectable marker gene can either be directly linked to the DNA sequence to be expressed or introduced into the same cell by co-transformation. Additional elements may also be required for optimal mRNA synthesis. These elements can include splice signals, as well as transcription promoters, enhancers, and termination signals.

[0390] After the expression vector or DNA sequence containing construct is prepared for expression, the expression vector can be transfected or introduced into suitable host cells.This can be achieved by using various techniques, such as protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid-based transfection or other conventional techniques.In the case of protoplast fusion, cells are grown in culture medium and screened for suitable activity.

[0391] Methods and conditions for culturing the resulting transfected cells and recovering the antibody molecules produced are known to those skilled in the art and can be modified or optimized based on the present specification depending on the particular expression vector and mammalian host cell used.

[0392] cell In another aspect, the application features host cells and vectors comprising the nucleic acids described herein. The nucleic acids can be present in a single vector or in separate vectors present in the same host cell or in separate host cells. The host cell can be a eukaryotic cell, such as a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, such as E. coli. For example, the mammalian cell can be a cultured cell or cell line. Exemplary mammalian cells include lymphocytic cell lines (e.g., NSO), Chinese hamster ovary cells (CHO), COS cells, oocytes, and cells derived from transgenic animals, such as mammary epithelial cells.

[0393] The present invention also provides host cells containing nucleic acid encoding the antibody molecules described herein. In one embodiment, the host cell is genetically engineered to contain nucleic acid encoding the antibody molecule.

[0394] In one embodiment, the host cell is genetically engineered by using an expression cassette. The term "expression cassette" refers to a nucleotide sequence that can achieve expression of a gene in a host compatible with such sequence. Such a cassette can include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors that are necessary or helpful to achieve expression, such as an inducible promoter, can also be used.

[0395] The present invention also provides a host cell comprising the vector described herein. Cells can be, but are not limited to, eukaryotic cells, bacterial cells, insect cells, or human cells.Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells, and MDCKII cells.Suitable insect cells include, but are not limited to, Sf9 cells.

[0396] use The methods described herein include, for example, using the pharmaceutical compositions described herein to treat a disorder, e.g., cancer, an autoimmune or inflammatory disorder, or an infectious disorder in a subject using an anti-NKp30 antibody molecule, e.g., a multispecific molecule described herein. Also provided are methods of reducing or ameliorating symptoms of a disorder, e.g., cancer, an autoimmune or inflammatory disorder, or an infectious disorder in a subject, as well as methods of inhibiting the proliferation of diseased cells, e.g., cancer cells, and / or killing or depleting one or more diseased cells, e.g., cancer cells. In embodiments, the methods described herein reduce the size of a tumor and / or reduce the number of cancer cells in a subject to which the methods described herein or pharmaceutical compositions described herein are administered.

[0397] In embodiments, the antibody molecule, e.g., multispecific molecule, or pharmaceutical composition is administered parenterally to the subject. In embodiments, the antibody molecule or pharmaceutical composition is administered intravenously, subcutaneously, intratumorally, intranodal, intramuscularly, intradermally, or intraperitoneally to the subject. In embodiments, the cells are administered, e.g., injected, directly into the tumor or lymph node. In embodiments, the cells are administered as an infusion (e.g., as described in Rosenberg et al., New Eng. J. of Med. 319:1676, 1988) or intravenous push. In embodiments, the cells are administered as an injectable depot formulation.

[0398] In an embodiment, the subject is a mammal.In an embodiment, the subject is a human, a monkey, a pig, a dog, a cat, a cow, a sheep, a goat, a rabbit, a rat, or a mouse.In an embodiment, the subject is a human.In an embodiment, the subject is a pediatric subject, for example, under 18 years old, for example, under 17 years old, under 16 years old, under 15 years old, under 14 years old, under 13 years old, under 12 years old, under 11 years old, under 10 years old, under 9 years old, under 8 years old, under 7 years old, under 6 years old, under 5 years old, under 4 years old, under 3 years old, under 2 years old, under 1 year old, or less than that. In embodiments, the subject is an adult, e.g., at least 18 years old, e.g., at least 19 years old, 20 years old, 21 years old, 22 years old, 23 years old, 24 years old, 25 years old, 25-30 years old, 30-35 years old, 35-40 years old, 40-50 years old, 50-60 years old, 60-70 years old, 70-80 years old, or 80-90 years old.

[0399] cancer In embodiments, the cancer is a hematological cancer, a solid tumor or a metastatic lesion thereof. In some embodiments, the anti-NKp30 antibody molecule used to treat cancer further comprises a tumor targeting moiety, for example, a tumor targeting moiety described herein.

[0400] In embodiments, the hematological cancer is leukemia or lymphoma. As used herein, "hematological cancer" refers to a tumor of the hematopoietic or lymphatic tissues, e.g., a tumor affecting the blood, bone marrow, or lymph nodes. Exemplary hematological malignancies include leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma (e.g., classical Hodgkin's lymphoma or nodular lymphocyte-predominant Hodgkin's lymphoma)), mycosis fungoides, non-Hodgkin's lymphoma (e.g., B-cell non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma), lymphoma, small lymphocytic lymphoma (CLL / SLL)), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma), or T-cell non-Hodgkin's lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system lymphoma, Sézary syndrome, Walden-Waldenström macroglobulinemia), chronic myeloproliferative neoplasm, Langerhans cell histiocytosis, multiple myeloma / plasma cell neoplasm, myelodysplastic syndrome, or myelodysplastic / myeloproliferative neoplasm.

[0401] In embodiments, the cancer is a solid tumor. Exemplary solid cancers include, but are not limited to, ovarian cancer, rectal cancer, stomach cancer, testicular cancer, cancer of the anal region, uterine cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, Kaposi's sarcoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, malignant melanoma of the skin or eye, uterine cancer, brain stem glioma, pituitary adenoma, epidermoid carcinoma, cancer of the cervical squamous cell carcinoma, cancer of the fallopian tubes, cancer of the endometrium, cancer of the vagina, sarcoma of soft tissue, cancer of the urethra, cancer of the vulva, cancer of the penis, cancer of the bladder, cancer of the kidney or ureter, cancer of the renal pelvis, spinal axis tumor, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of the above cancers, or combinations thereof.

[0402] In certain embodiments, the cancer is an epithelial, mesenchymal or hematological malignancy. In certain embodiments, the cancer to be treated is a solid tumor (e.g., carcinoid, carcinoma or sarcoma), a soft tissue tumor (e.g., a hemolytic malignancy), and a metastatic lesion, such as a metastatic lesion of any of the cancers disclosed herein. In one embodiment, the cancer to be treated is a fibrotic or desmoplastic solid tumor, such as a tumor with one or more of limited tumor perfusion, vascular compression, fibrotic tumor stroma, or increased interstitial fluid pressure. In one embodiment, the solid tumor is selected from one or more of pancreatic cancer (e.g., pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma), breast cancer, colon cancer, colorectal cancer, lung cancer (e.g., small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC)), skin cancer, ovarian cancer, liver cancer, esophageal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, or prostate cancer.

[0403] Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.More specific examples of such cancer are described below and include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer including small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous cell carcinoma of the lung, peritoneal cancer, hepatocellular carcinoma, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatoma, anal cancer, and penile cancer, and head and neck cancer. The term "cancer" refers to a primary malignant cell or tumor (e.g., cells that have not migrated to sites in a subject's body other than the site of the original malignant tumor or tumor), as well as a secondary malignant cell or tumor. Includes tumors (eg, metastases, resulting from the migration of malignant or tumor cells to secondary sites distinct from the site of the original tumor).

[0404] Other examples of cancer or malignant tumors include, but are not limited to, acute childhood lymphoblastic leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, adult (primary) hepatocellular carcinoma, adult (primary) liver cancer, adult acute lymphocytic leukemia, adult acute myeloid leukemia, adult Hodgkin's disease, adult Hodgkin's lymphoma, adult lymphocytic leukemia, adult non-Hodgkin's lymphoma, adult primary liver cancer, adult soft tissue sarcoma, AIDS-related lymphoma, AIDS-related malignancies, anal cancer, astrocytoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor tumors, breast cancer, cancer of the renal pelvis and ureter, central nervous system (primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, brain astrocytoma, neck cancer, childhood (primary) hepatocellular carcinoma, childhood (primary) liver cancer, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood brain astrocytoma, childhood extracranial germ cell tumors, childhood Hodgkin's disease, childhood Hodgkin's lymphoma, childhood hypothalamic and visual pathway glioma, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkin's lymphoma, childhood pineal and supratentorial primitive neuroectodermal tumors , primary pediatric liver cancer, pediatric rhabdomyosarcoma, pediatric soft tissue sarcoma, pediatric visual pathway and hypothalamic glioma, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, cutaneous T-cell lymphoma, endocrine pancreatic islet cell carcinoma, endometrial cancer, ependymoma, epithelial carcinoma, esophageal cancer, Ewing's sarcoma and related tumors, exocrine pancreatic cancer, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancer, female breast cancer, Gaucher disease, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal tumors, germ cell tumors, gestational trophoblastic tumors, hairy cell leukemia, head and neck cancer, hepatocellular carcinoma, ho Hodgkin's disease, Hodgkin's lymphoma, Hypergammaglobulinemia, Hypopharyngeal cancer, Intestinal cancer, Intraocular melanoma, Islet cell carcinoma, Islet cell pancreatic cancer, Kaposi's sarcoma, Kidney cancer, Laryngeal cancer, Lip and oral cavity cancer, Liver cancer, Lung cancer, Lymphoproliferative disorders, Macroglobulinemia, Hepatic and male breast cancer, Malignant mesothelioma, Malignant thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic occult primary squamous cell neck cancer, Metastatic primary squamous cell neck cancer, Metastatic squamous cell neck cancer, Multiple myeloma, Multiple myeloma / plasma cell neoplasm, Myelodysplastic syndrome, Myelogenous leukemia, Myeloid leukemiaLeukemia), myeloproliferative disorders, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma during pregnancy, non-melanoma skin cancer, non-small cell lung cancer, occult primary metastatic squamous cell neck cancer, oropharyngeal cancer, bone / malignant fibrous sarcoma, osteosarcoma / malignant fibrous histiocytoma, osteosarcoma / malignant fibrous histiocytoma of bone, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant tumor, pancreatic cancer, paraproteinemia, purpura, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, plasma cell neoplasm / multiple myeloma, primary central nervous system lymphoma, primary liver cancer, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter cancer, retinoblastoma, These include rhabdomyosarcoma, salivary gland cancer, sarcoidosis sarcoma, Sezary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell cervical cancer, gastric cancer, supratentorial primitive neuroectodermal and pineal tumors, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, transitional renal pelvis and ureter cancer, trophoblastic tumor, ureteral and renal pelvic cell carcinoma, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, and any other hyperproliferative disease other than neoplasms in the organ systems listed above.

[0405] In other embodiments, the multispecific molecules are used to treat hyperproliferative disorders, such as hyperproliferative connective tissue disorders (e.g., hyperproliferative fibrotic diseases), as described above and herein. In one embodiment, the hyperproliferative fibrotic disease is multi-organ specific or organ specific. Exemplary hyperproliferative fibrotic diseases include, but are not limited to, multi-organ specific disorders (e.g., systemic sclerosis, multifocal fibrosclerosis, sclerosing graft-versus-host disease in bone marrow transplant recipients, nephrogenic systemic fibrosis, scleroderma) and organ specific disorders (e.g., fibrosis of the eye, lung, liver, heart, kidney, pancreas, skin and other organs). In other embodiments, the disorder is selected from cirrhosis or tuberculosis. In another embodiment, the disorder is leprosy.

[0406] In embodiments, the multispecific molecule (or pharmaceutical composition) is administered in a manner appropriate for the disease to be treated or prevented. The number and frequency of administration will be determined by factors such as the condition of the patient and the type and severity of the patient's disease. Appropriate dosages can be determined by clinical trials. For example, when an "effective amount" or a "therapeutically effective amount" is indicated, the exact amount of pharmaceutical composition (or multispecific molecule) to be administered can be determined by a physician, taking into account individual differences in tumor size, extent of infection or metastasis, age, weight, and condition of the subject. In embodiments, the pharmaceutical compositions described herein are administered in a manner appropriate for the disease to be treated or prevented. 4 ~10 9 cells / kg body weight, e.g., 10 5 ~10 6 The pharmaceutical compositions described herein may be administered at a dosage of 1000 cells / kg body weight, including all integer values ​​within these ranges. In embodiments, the pharmaceutical compositions described herein may be administered multiple times at these dosages. In embodiments, the pharmaceutical compositions described herein may be administered using injection techniques described in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988).

[0407] In an embodiment, the cancer is a myeloproliferative neoplasm, such as primary or idiopathic myelofibrosis (MF), essential thrombocytosis (ET), polycythemia vera (PV), or chronic myelogenous leukemia (CML). In an embodiment, the subject has myelofibrosis. In an embodiment, the subject has a calreticulin mutation, such as a calreticulin mutation disclosed herein. In an embodiment, the subject does not have a JAK2-V617F mutation. In an embodiment, the subject has a JAK2-V617F mutation. In an embodiment, the subject has an MPL mutation. In an embodiment, the subject does not have an MPL mutation.

[0408] In embodiments, the cancer is a solid tumor. Exemplary solid cancers include, but are not limited to, ovarian cancer, rectal cancer, stomach cancer, testicular cancer, cancer of the anal region, uterine cancer, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, Kaposi's sarcoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, malignant melanoma of the skin or eye, uterine cancer, brain stem glioma, pituitary adenoma, epidermoid carcinoma, cancer of the cervical squamous cell carcinoma, cancer of the fallopian tubes, cancer of the endometrium, cancer of the vagina, sarcoma of soft tissue, cancer of the urethra, cancer of the vulva, cancer of the penis, cancer of the bladder, cancer of the kidney or ureter, cancer of the renal pelvis, spinal axis tumor, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, metastatic lesions of the above cancers, and combinations thereof.

[0409] Inflammatory and autoimmune disorders In some embodiments, the anti-NKp30 antibody molecules, e.g., multispecific antibody molecules, disclosed herein can be used to treat inflammatory and autoimmune diseases, as well as graft-versus-host disease (GvHD). In some embodiments, the antibody molecules, e.g., multispecific antibody molecules, disclosed herein deplete autoreactive autologous T cells, e.g., by directing NK cells, e.g., NKp30-expressing cells, to autoreactive T cells. In some embodiments, the anti-NKp30 antibody molecule further comprises a binding specificity that binds to an antigen present on the surface of an autoreactive T cell, e.g., an autoreactive T cell associated with an inflammatory or autoimmune disorder.

[0410] As used herein, the term "autoimmune" disease, disorder, or condition refers to a disease in which the body's immune system attacks its own cells or tissues. Autoimmune diseases can result in the production of autoantibodies that are inappropriately produced and / or overproduced against the body's own antigens or self-antigens. Autoimmune diseases include, but are not limited to, cardiovascular, rheumatic, glandular, gastrointestinal, skin, liver, neurological, muscular, renal, reproductive, connective tissue, and systemic diseases. In some embodiments, Autoimmune diseases can be mediated by T cells, B cells, innate immune cells (eg, macrophages, eosinophils, or natural killer cells), or complement-mediated pathways.

[0411] Examples of autoimmune disorders that can be treated by administering the antibodies of the invention include limited alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune disease of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune folliculitis and orchitis, autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, primary fibromyalgia, glomerulonephritis, Graves' disease, Guillain-Barr, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA neuropathy. The conditions and conditions that may be treated with the present invention include, but are not limited to, juvenile arthritis, lichen planus, systemic lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, neuromyelitis optica (NMO), type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychronitis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff man syndrome, systemic lupus erythematosus, lupus erythematosus, Takayasu's arteritis, temporal arteritis / giant cell arteritis, transverse myelitis, ulcerative colitis, uveitis, vasculitis such as dermatitis herpetiformis vasculitis, vitiligo, and Wegener's granulomatosis. In some embodiments, the autoimmune disorder is SLE or type 1 diabetes.

[0412] Examples of inflammatory disorders that can be prevented, treated or managed according to the methods of the present invention include, but are not limited to, asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacterial infection.

[0413] Thus, the anti-NKp30 antibody molecules, eg, multispecific molecules, of the invention have utility in the treatment of inflammatory and autoimmune diseases. infectious disease In some embodiments, the anti-NKp30 antibody molecule, e.g., multispecific antibody molecule, disclosed herein can be used to treat infectious diseases. In some embodiments, the antibody molecule, e.g., multispecific antibody molecule, disclosed herein depletes cells expressing viral or bacterial antigens. In some embodiments, the anti-NKp30 antibody molecule further comprises a binding specificity that binds to an antigen present on the surface of an infected cell, e.g., a virally infected cell.

[0414] Some examples of pathogenic viruses causing infections treatable by the methods include HIV, hepatitis (A, B, or C), herpes viruses (e.g., VZV, HSV-1, HSV-6, HSV-II, and CMV, Epstein-Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackievirus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum contagiosum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus. In one embodiment, the infection is an influenza infection.

[0415] In another embodiment, the infection is a hepatitis infection, for example a hepatitis B or hepatitis C infection. Exemplary viral diseases that can be treated include Epstein-Barr virus (EBV), influenza virus, HIV, SIV, tuberculosis, malaria, and HCMV. Some examples of pathogenic bacteria causing infectious diseases treatable by the method of the present invention include, but are not limited to, syphilis, chlamydia, rickettsia bacteria, mycobacteria, staphylococci, streptococci, pneumococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacillus, cholera, tetanus, botulinum, anthrax, leptospira, and lyme disease bacteria. Anti-NKp30 antibody molecules can be used in combination with existing treatment methods for the aforementioned infections. For example, treatments for syphilis include penicillin (e.g., penicillin G), tetracycline, doxycycline, ceftriaxone, and azithromycin.

[0416] Diagnostic Use In one aspect, the present invention provides a diagnostic method for detecting the presence of NKp30 protein in vitro (e.g., in a biological sample such as a tissue biopsy), e.g., from a cancerous tissue) or in vivo (e.g., in vivo imaging in a subject). The method includes the steps of (i) contacting the sample with an antibody molecule described herein, or administering the antibody molecule to a subject; (optionally) (ii) contacting with a reference sample, e.g., a control sample (e.g., a control biological sample such as plasma, tissue, biopsy, etc.) or a control subject); and (iii) detecting the formation of a complex between the antibody molecule and the sample or subject, or a control feed or control, wherein a change, e.g., a substantially significant change, in the formation of the complex in the sample or subject relative to the control sample or control indicates the presence of NKp30 in the sample. The antibody molecule can be directly or indirectly labeled with a detectable substance to facilitate detection of bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, and radioactive materials, as described above and in more detail below.

[0417] The term "sample", when referring to a sample used to detect a polypeptide, includes, but is not limited to, a cell, a cell lysate, a protein or membrane extract of a cell, a body fluid, or a tissue sample.

[0418] Complex formation between the antibody molecule and NKp30 can be detected by measuring or visualizing either the binding molecule bound to the NKp30 antigen or the binding molecule not bound. Conventional detection assays, such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or tissue immunohistochemistry, can be used. Instead of labeling the antibody molecule, the presence of NKp30 can be assayed in the sample by a competitive immunoassay that utilizes a standard labeled with a detectable substance and an unlabeled antibody molecule. In this assay, the biological sample, the labeled standard and the antibody molecule are combined and the amount of the labeled standard bound to the unlabeled binding molecule is determined. The amount of NKp30 in the sample is inversely proportional to the amount of the labeled standard bound to the antibody molecule. EXAMPLES

[0419] The following examples are set forth to aid in the understanding of the present invention, but are not intended, and should not be construed, as limiting its scope in any manner.

[0420] Example 1: Immunization of Armenian hamsters to generate anti-NKp30 antibodies Briefly, Armenian hamsters were immunized with the extracellular domain of human NKp30 protein in complete Freund's adjuvant and boosted twice with NKp30 in incomplete Freund's adjuvant (IFA) on days 14 and 28. One further boost in IFA was given on day 56 and animals were harvested 3 days later. Spleens were harvested and fused with the P3X63Ag8.653 mouse myeloma cell line. 0.9×10 in 125 ul ^5 cells / well were plated in 96-well plates and fed with HAT or HT for selection, and 125 μl of I-20+2ME+HAT (IMDM (4 g / L glucose) supplemented with 20% fetal bovine serum, 4 mM L-glutamine, 1 mM sodium pyruvate, 50 U penicillin, 50 μg streptomycin and 50 μM 2-ME in the absence or presence of Hybridoma Cloning Factor (1% final) on days 7, 11 and thereafter as appropriate. Supernatants were collected approximately 2 weeks after fusion (cells were approximately 50% confluent) and assayed for binding.

[0421] Example 2: Hybridoma screening for NKp30 mAb Expi293 cells were transfected with BG160 (hNKp30 cell antigen) and screened 18 hours later. On the day of screening, 0.05 × 10 transfected cells were ^6 100 μg / mL and anti-Armenian hamster Fc Alexa Fluor 488 was added to a final concentration of 0.4ug / mL. 50uL (2,500 cells) of this mixture was added to each well of a 384-well plate. The same density of non-transfected 293 cells along with the secondary were used as negative controls. 5uL of hybridoma supernatant was added to the cell mixture and the plate was incubated at 37°C for 1 hour. The plate was then imaged on a Mirrorball. Positive clones were identified and subcloned by serial dilution to obtain clonally selected hybridomas. Hybridoma cells were harvested after reconfirmation using the same protocol and the corresponding heavy and light chain sequences were obtained. DNA was subcloned into pcDNA3.4 for subsequent expression of the corresponding antibodies and further validation.

[0422] Example 3: Binding of NKp30 antibodies to NK92 cells NK-92 cells were washed with PBS containing 0.5% BSA and 0.1% sodium azide (staining buffer) and added to 96-well V-bottom plates at 200,000 cells / well. Hamster NKp30 antibody was added to the cells at 2.0-fold serial dilutions and incubated for 1 hour at room temperature. Plates were washed twice with staining buffer. Secondary antibody against hamster Fc conjugated to AF647 (Jackson, 127-605-160) was added at 1:100 dilution (1.4 mg / ml stock) and incubated with the cells for 30 minutes at 4° C., followed by washing with staining buffer. Cells were then fixed with 4% paraformaldehyde for 10 minutes at room temperature. Plates were read on a CytoFLEX LS (Beckman Coulter). Data was calculated as percent-AF747 positive population (FIG. 1).

[0423] Example 4: Bioassay to measure activity of NKp30 antibodies using the NK92 cell line NKp30 antibodies were serially diluted 3-fold in PBS and incubated overnight at 2-8°C in flat-bottom 96-well plates. Plates were washed twice in PBS and 40,000 NK-92 cells were added in growth medium containing IL-2. Supernatants were collected after incubating plates for 16-24 hours in a humidified incubator at 37°C and 5% CO2. IFNγ levels in the supernatants were measured according to the MSD assay instructions (Figure 2). Supernatants collected from cells incubated with hamster isotype IgG were used as a negative control and supernatants from cells incubated with NKp30 monoclonal antibody (R&D, clone 210847) served as a positive control. Data were generated using hamster anti-NKp30 mAB.

[0424] Example 5: Generation and characterization of humanized anti-NKp30 antibodies A series of hamster anti-NKp30 antibodies were selected. These antibodies were shown to bind to human NKp30 and cynomolgus monkey NKp30 and induce IFNγ production from NK-90 cells (data not shown). Exemplary hamster anti-NKp30 antibodies 15E1, 9G1, The VH and VL sequences of 15H6, 9D9, 3A12, and 12D10 are disclosed in Table 9. The VH and VL sequences of exemplary humanized anti-NKp30 antibodies based on 15E1, 9G1, and 15H6 are also disclosed in Table 9. The Kabat CDRs of these antibodies are disclosed in Tables 18 and 8.

[0425] Two humanized constructs based on 15E1 were selected. The first construct BJM0407 is a Fab comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7302 and a lambda light chain variable region comprising the amino acid sequence of SEQ ID NO: 7305. Its corresponding scFv construct BJM0859 comprises the amino acid sequence of SEQ ID NO: 7310. The second construct BJM0411 is a Fab comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7302 and a kappa light chain variable region comprising the amino acid sequence of SEQ ID NO: 7309. Its corresponding scFv construct BJM0860 comprises the amino acid sequence of SEQ ID NO: 7311. BJM0407 and BJM0411 showed comparable biophysical characteristics, such as binding affinity to NKp30 and thermal stability. The scFv constructs BJM0859 and BJM0860 also showed comparable biophysical properties.

[0426] Incorporation by Reference All publications, patents, and accession numbers mentioned in this specification are incorporated by reference in their entirety into this specification as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

[0427] equivalent Although specific embodiments of the present invention have been discussed, the above specification is illustrative and not restrictive. Numerous variations of the present invention will become apparent to those skilled in the art upon consideration of this specification and the following claims. The full scope of the present invention should be determined by reference to the claims, their full scope of equivalents, and the specification, together with such variations. This specification includes the following disclosure of the invention. [Item 1] An isolated antibody molecule that binds to NKp30, (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 7313 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 7315 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions); Also / or (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 7326 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 7327 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 7329 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). An antibody molecule comprising: [Item 2] The antigen-binding domain is (i) a VH comprising an amino acid sequence of any one of SEQ ID NOs: 7298 or 7300 to 7304 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 7298 or 7300 to 7304); and / or (ii) a VL comprising any one of the amino acid sequences of SEQ ID NOs: 7299 or 7305 to 7309 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 7299 or 7305 to 7309); The antibody molecule of item 1, comprising: [Item 3] The antigen-binding domain is (i)) a VH comprising the amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising the amino acid sequence of SEQ ID NO: 7305 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7305); or (ii) a VH comprising the amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising the amino acid sequence of SEQ ID NO: 7309 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7309). The antibody molecule according to item 2, comprising: [Item 4] The antigen-binding domain is (i) the amino acid sequence of SEQ ID NO: 7310 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7310); or (ii) the amino acid sequence of SEQ ID NO: 7311 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7311); 4. The antibody molecule according to any one of items 1 to 3, comprising: [Item 5] An isolated antibody molecule that binds to NKp30, (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6000 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6063 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6064 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 7293 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). An antibody molecule comprising: [Item 6] The antigen-binding domain is (1) a heavy chain variable region (VH) comprising a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6003 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR2 amino acid sequence of SEQ ID NO: 6004 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO: 6005 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VHFWR4 amino acid sequence of SEQ ID NO: 6006 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom); and / or (2) A light chain framework region (VLFWR1) amino acid sequence of SEQ ID NO: 6066 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6067 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 7292 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VLFWR4 amino acid sequence of SEQ ID NO: 6069 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom). A light chain variable region (VL) comprising: 6. The antibody molecule according to item 5, comprising: [Item 7] The antigen-binding domain is (i) a VH comprising the amino acid sequence of SEQ ID NO: 6121 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6121); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 7294 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 7294). 7. The antibody molecule according to item 5 or 6, comprising: [Item 8] The antigen-binding domain is (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6007 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6008 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6009 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6071 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 6072 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). 8. The antibody molecule according to any of items 5 to 7, comprising: [Item 9] The antigen-binding domain is (1) a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6010 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6011 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6012 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations therefrom, e.g., substitutions, additions, or deletions), or a heavy chain variable region (VH) comprising the VHFWR4 amino acid sequence of SEQ ID NO: 6013 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom); and / or (2) A light chain framework region (VLFWR1) amino acid sequence of SEQ ID NO: 6073 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6074 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 6075 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VLFWR4 amino acid sequence of SEQ ID NO: 6076 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom). A light chain variable region (VL) comprising: 9. The antibody molecule according to any of items 5 to 8, comprising: [Item 10] The antigen-binding domain is (i) a VH comprising the amino acid sequence of SEQ ID NO: 6122 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6122); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 6136 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6136). 10. The antibody molecule according to any one of items 5 to 9, comprising: [Item 11] A multispecific molecule comprising an antibody molecule described in any one of items 1 to 10. [Item 12] a. A tumor targeting moiety, e.g., as described herein; b. A cytokine molecule, e.g., as described herein; c. A T cell engager, e.g., as described herein; or d. A stromal-modifying moiety, e.g., as described herein. 12. The multispecific molecule of item 11, further comprising one, two, three, four or more of: [Item 13] The multispecific molecule of Item 11, further comprising a binding specificity that binds to an antigen present on the surface of an autoreactive T cell, e.g., an autoreactive T cell associated with an inflammatory or autoimmune disorder. [Item 14] The multispecific molecule of Item 11, further comprising a binding specificity that binds to an infected cell, e.g., a virus- or bacteria-infected cell. [Item 15] An antibody molecule according to any one of items 1 to 10 or a multispecific molecule according to any one of items 11 to 14, which is a monospecific antibody molecule, a bispecific antibody molecule, or a trispecific antibody molecule. [Item 16] An antibody molecule according to any one of items 1 to 10 or a multispecific molecule according to any one of items 11 to 14, which is a monovalent antibody molecule, a divalent antibody molecule, or a trivalent antibody molecule. [Item 17] The antibody molecule according to any one of items 1 to 10, 15 or 16, or the multispecific molecule according to any one of items 11 to 15, which is a full-length antibody (e.g., an antibody comprising at least one, preferably two complete heavy chains and at least one, preferably two complete light chains) or an antigen-binding fragment (e.g., a Fab, F(ab')2, Fv, single-chain Fv, single-domain antibody, diabody (dAb), bivalent antibody, or bispecific antibody or fragment thereof, single-domain variant thereof, or camelid antibody). [Item 18] The antibody molecule or multispecific molecule according to any one of Items 1 to 17, comprising a heavy chain constant region, or a fragment thereof, selected from IgG1, IgG2, IgG3, or IgG4. [Item 19] An antibody molecule or multispecific molecule described in any one of items 1 to 18, comprising a light chain constant region selected from the light chain constant regions of kappa or lambda, or a fragment thereof. [Item 20] The immunoglobulin chain constant region (e.g., Fc region) is capable of binding to Fc receptors, anti- 20. The antibody or multispecific molecule of any of items 1 to 19, which is altered, e.g. mutated, to increase or decrease one or more of: total glycosylation, number of cysteine ​​residues, effector cell function, or complement function. [Item 21] The antibody molecule or multispecific molecule of any of items 1 to 20, wherein the interface of the first and second immunoglobulin chain constant regions (e.g., Fc regions) is altered, e.g., mutated, to increase or decrease dimerization, e.g., compared to an unengineered interface. [Item 22] The antibody molecule or multispecific molecule of item 21, wherein dimerization of immunoglobulin chain constant regions (e.g., Fc regions) is enhanced by providing one or more of paired holes and protrusions ("knobs-in-holes"), electrostatic interactions, or chain exchange at the Fc interface of the first and second Fc regions, thereby forming, for example, a higher ratio of heteromultimers:homomultimers compared to an interface that is not engineered. [Item 23] The antibody molecule or multispecific molecule of item 21 or 22, wherein the immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution at one or more of positions 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409 of the Fc region of human IgG1, for example. [Item 24] The antibody molecule or multispecific molecule of Item 21, wherein the immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution selected from T366S, L368A, or Y407V (e.g., corresponding to a pore or hole), or T366W (e.g., corresponding to a protrusion or knob), or a combination thereof. [Item 25] The antibody molecule or multispecific molecule of any of items 1 to 24, further comprising a linker, e.g., a linker between one or more of the targeting moiety and the cytokine molecule or stromal modifying moiety, the targeting moiety and the immune cell engager, cytokine molecule or stromal modifying moiety, and the immune cell engager, cytokine molecule or stromal modifying moiety and an immunoglobulin chain constant region (e.g., an Fc region), the targeting moiety and an immunoglobulin chain constant region, or the immune cell engager and an immunoglobulin chain constant region. [Item 26] The antibody molecule or multispecific molecule described in Item 25, wherein the linker is selected from a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker. [Item 27] ​​The antibody molecule or multispecific molecule described in Item 26, wherein the linker is a peptide linker. [Item 28] An antibody molecule or multispecific molecule described in Item 27, wherein the peptide linker comprises Gly and Ser. [Item 29] An isolated nucleic acid molecule comprising a nucleotide sequence encoding any of the antibody molecules or multispecific or multifunctional molecules described herein, or a nucleotide sequence that is substantially homologous thereto (e.g., at least 95% to 99.9% identical thereto). [Item 30] An isolated nucleic acid encoding an antibody molecule or multispecific molecule described in any one of items 1 to 29. [Item 31] A vector, e.g., an expression vector, comprising one or more of the nucleic acid molecules described in items 29 or 30. [Item 32] A host cell comprising a nucleic acid molecule or vector described in any one of items 29 to 31. [Item 33] A method for making, e.g., producing, an antibody molecule or a multispecific or multifunctional molecule polypeptide described in any one of items 1 to 28, comprising culturing a host cell described in item 32 under appropriate conditions, e.g., conditions suitable for gene expression and / or homo- or heterodimerization. [Item 34] A pharmaceutical comprising an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any one of items 1 to 28 and a pharma- ceutically acceptable carrier, excipient or stabilizer. composition. [Item 35] A method for treating cancer, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any one of Items 1 to 12 or 15 to 28, wherein the multispecific antibody is administered in an amount effective to treat the cancer. [Item 36] An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of items 1 to 12 or 15 to 28 for use in treating cancer. [Item 37] The method according to Item 35 or the use according to Item 36, wherein the cancer is a solid tumor cancer or a metastatic lesion. [Item 38] The method according to item 37 or the use according to item 37, wherein the solid tumor cancer is one or more of pancreatic cancer (e.g., pancreatic adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g., small cell or non-small cell lung cancer), skin cancer, ovarian cancer, or liver cancer. [Item 39] The method according to Item 35 or the use according to Item 36, wherein the cancer is blood cancer. [Item 40] The method according to any one of items 35 or 37 to 39 or the use according to any one of items 36 to 39, further comprising a step of administering a second therapeutic treatment. [Item 41] The method according to Item 40 or the use according to Item 40, wherein the second therapeutic treatment comprises a therapeutic agent (e.g., a chemotherapeutic agent, a biological agent, a hormonal therapy), radiation, or surgery. [Item 42] The method according to Item 41 or the use according to Item 41, wherein the therapeutic agent is selected from a chemotherapeutic agent or a biological agent. [Item 43] A method for treating an autoimmune or inflammatory disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any one of Items 1 to 11, 13, or 15 to 28, wherein the multispecific antibody is administered in an amount effective to treat the autoimmune or inflammatory disorder. [Item 44] An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of Items 1 to 11, 13 or 15 to 28 for use in treating an autoimmune or autoinflammatory disorder. [Item 45] A method for treating an infectious disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any one of Items 1 to 11 or 14 to 28, wherein the multispecific antibody is administered in an amount effective to treat the infectious disorder. [Item 46] An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of items 1 to 11 or 14 to 28 for use in treating an infectious disorder.

Claims

1. 1. An isolated antibody molecule that binds to NKp30, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 7313 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 7315 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions); and / or (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 7326 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 7327 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 7329 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). An antibody molecule comprising:

2. The antigen-binding domain comprises: (i) a VH comprising an amino acid sequence of any of SEQ ID NOs: 7298 or 7300-7304 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to any of SEQ ID NOs: 7298 or 7300-7304); and / or (ii) a VL comprising an amino acid sequence of any one of SEQ ID NOs: 7299 or 7305-7309 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to any one of SEQ ID NOs: 7299 or 7305-7309); The antibody molecule of claim 1 , comprising:

3. The antigen-binding domain comprises: (i)) a VH comprising the amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising the amino acid sequence of SEQ ID NO: 7305 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7305); or (ii) a VH comprising an amino acid sequence of SEQ ID NO: 7302 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7302), and a VL comprising an amino acid sequence of SEQ ID NO: 7309 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7309). The antibody molecule of claim 2, comprising:

4. The antigen-binding domain comprises: (i) the amino acid sequence of SEQ ID NO: 7310 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7310); or (ii) the amino acid sequence of SEQ ID NO: 7311 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to 7311). The antibody molecule of any one of claims 1 to 3, comprising:

5. 1. An isolated antibody molecule that binds to NKp30, comprising: (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6000 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6001 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6002 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6063 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6064 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 7293 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions). An antibody molecule comprising:

6. The antigen-binding domain comprises: (1) a heavy chain variable region (VH) comprising a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6003 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR2 amino acid sequence of SEQ ID NO: 6004 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VHFWR3 amino acid sequence of SEQ ID NO: 6005 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VHFWR4 amino acid sequence of SEQ ID NO: 6006 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom); and / or (2) A light chain framework region (VLFWR1) amino acid sequence of SEQ ID NO: 6066 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6067 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 7292 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VLFWR4 amino acid sequence of SEQ ID NO: 6069 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom). A light chain variable region (VL) comprising: The antibody molecule of claim 5 .

7. The antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 6121 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6121); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 7294 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 7294). The antibody molecule of claim 5 or 6, comprising:

8. The antigen-binding domain comprises: (i) a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 6007 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VHCDR2 amino acid sequence of SEQ ID NO: 6008 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VHCDR3 amino acid sequence of SEQ ID NO: 6009 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), A heavy chain variable region (VH) containing a sequence having mutations, e.g., substitutions, additions, or deletions; and (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 6070 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), a VLCDR2 amino acid sequence of SEQ ID NO: 6071 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions), and / or a VLCDR3 amino acid sequence of SEQ ID NO: 6072 (or a sequence having no more than 1, 2, 3, or 4 mutations, e.g., substitutions, additions, or deletions).

8. The antibody molecule of claim 5 , comprising:

9. The antigen-binding domain comprises: (1) a heavy chain variable region (VH) comprising a heavy chain framework region 1 (VHFWR1) amino acid sequence of SEQ ID NO: 6010 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR2 amino acid sequence of SEQ ID NO: 6011 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), a VHFWR3 amino acid sequence of SEQ ID NO: 6012 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), or a VHFWR4 amino acid sequence of SEQ ID NO: 6013 (or a sequence having no more than 1, 2, 3, 4, 5, or 6 mutations therefrom, e.g., substitutions, additions, or deletions), and / or (2) A light chain framework region (VLFWR1) amino acid sequence of SEQ ID NO: 6073 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR2 amino acid sequence of SEQ ID NO: 6074 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), a VLFWR3 amino acid sequence of SEQ ID NO: 6075 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom), or a VLFWR4 amino acid sequence of SEQ ID NO: 6076 (or a sequence having 1, 2, 3, 4, 5, or 6 or less mutations, e.g., substitutions, additions, or deletions therefrom). A light chain variable region (VL).

9. The antibody molecule of claim 5 , comprising:

10. The antigen-binding domain comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 6122 (or an amino acid sequence having at least about 75%, 80%, 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 6122); and / or (ii) a VL comprising the amino acid sequence of SEQ ID NO: 6136 (or an amino acid sequence having at least about 93%, 95%, or 99% sequence identity to SEQ ID NO: 6136).

10. The antibody molecule of claim 5 , comprising:

11. A multispecific molecule comprising an antibody molecule according to any one of claims 1 to 10.

12. a. a tumor targeting moiety, e.g., as described herein; b. a cytokine molecule, e.g., as described herein; c. a T cell engager, e.g., as described herein; or d. e.g., a stromal-modifying moiety as described herein. The multispecific molecule of claim 11 , further comprising one, two, three, four or more of:

13. The multispecific antibody of claim 11 further comprises a binding specificity that binds to an antigen present on the surface of an autoreactive T cell, e.g., an autoreactive T cell associated with an inflammatory or autoimmune disorder. sex molecule.

14. The multispecific molecule of claim 11 further comprising a binding specificity that binds to an infected cell, e.g., a virus- or bacteria-infected cell.

15. An antibody molecule according to any one of claims 1 to 10 or a multispecific molecule according to any one of claims 11 to 14, which is a monospecific antibody molecule, a bispecific antibody molecule or a trispecific antibody molecule.

16. An antibody molecule according to any one of claims 1 to 10 or a multispecific molecule according to any one of claims 11 to 14, which is a monovalent, divalent or trivalent antibody molecule.

17. A full length antibody (e.g., an antibody comprising at least one, and preferably two, complete heavy chains and at least one, and preferably two, complete light chains), or an antigen-binding fragment (e.g., Fab, F(ab') ２ , Fv, single chain Fv, single domain antibody, diabody (dAb), bivalent antibody, or bispecific antibody or fragment thereof, single domain variant thereof, or camelid antibody).

18. 18. An antibody molecule or multispecific molecule according to any preceding claim, comprising a heavy chain constant region, or a fragment thereof, selected from IgG1, IgG2, IgG3, or IgG4.

19. 19. An antibody molecule or multispecific molecule according to any preceding claim, comprising a light chain constant region selected from the kappa or lambda light chain constant regions, or a fragment thereof.

20. 20. The antibody or multispecific molecule of any one of claims 1 to 19, wherein the immunoglobulin chain constant region (e.g., the Fc region) is altered, e.g., mutated, to increase or decrease one or more of Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function.

21. 21. An antibody molecule or multispecific molecule according to any one of claims 1 to 20, wherein the interface of the first and second immunoglobulin chain constant regions (e.g. Fc regions) is altered, e.g. mutated, to increase or decrease dimerization, e.g. compared to an unengineered interface.

22. 22. The antibody or multispecific molecule of claim 21 , wherein dimerization of immunoglobulin chain constant regions (e.g., Fc regions) is enhanced by providing one or more of paired holes and protrusions ("knobs-in-holes"), electrostatic interactions, or chain exchange at the Fc interface of the first and second Fc regions, thereby forming, e.g., a higher ratio of heteromultimers:homomultimers compared to a non-engineered interface.

23. 23. The antibody molecule or multispecific molecule of claim 21 or 22, wherein the immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution at one or more of positions 347, 349, 350, 351, 366, 368, 370, 392, 394, 395, 397, 398, 399, 405, 407, or 409, e.g., of the human IgG1 Fc region.

24. The immunoglobulin chain constant region (e.g., Fc region) comprises an amino acid substitution selected from T366S, L368A, or Y407V (e.g., corresponding to a pore or hole), or T366W (e.g., corresponding to a protuberance or knob), or a combination thereof.

22. An antibody molecule or multispecific molecule according to claim 21.

25. 25. The antibody molecule or multispecific molecule of any of claims 1 to 24, further comprising a linker, e.g., a linker between one or more of the targeting moiety and the cytokine molecule or stromal modifying moiety, the targeting moiety and the immune cell engager, cytokine molecule or stromal modifying moiety, and the immune cell engager, cytokine molecule or stromal modifying moiety and an immunoglobulin chain constant region (e.g., an Fc region), the targeting moiety and an immunoglobulin chain constant region, or the immune cell engager and an immunoglobulin chain constant region.

26. 26. The antibody molecule or multispecific molecule of claim 25, wherein the linker is selected from a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, or a non-helical linker.

27. 27. The antibody molecule or multispecific molecule of claim 26, wherein the linker is a peptide linker.

28. 28. The antibody molecule or multispecific molecule of claim 27, wherein the peptide linker comprises Gly and Ser.

29. An isolated nucleic acid molecule comprising a nucleotide sequence encoding any of the antibody molecules or multispecific or multifunctional molecules described herein, or a nucleotide sequence substantially homologous thereto (e.g., at least 95% to 99.9% identical thereto).

30. 30. An isolated nucleic acid encoding an antibody molecule or a multispecific molecule according to any one of claims 1 to 29.

31. 31. A vector, e.g. an expression vector, comprising one or more of the nucleic acid molecules of claim 29 or 30.

32. 32. A host cell comprising a nucleic acid molecule or vector according to any one of claims 29 to 31.

33. A method for making, e.g. producing, an antibody molecule or multispecific or multifunctional molecule polypeptide according to any one of claims 1 to 28, comprising culturing a host cell according to claim 32 under suitable conditions, e.g. conditions suitable for gene expression and / or homo- or heterodimerization.

34. 29. A pharmaceutical composition comprising an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any one of claims 1 to 28, together with a pharma- ceutically acceptable carrier, excipient or stabilizer.

35. 30. A method of treating cancer comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 12 or 15 to 28, wherein the multispecific antibody is administered in an amount effective to treat the cancer.

36. 30. An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 12 or 15 to 28 for use in treating cancer.

37. 37. The method according to claim 35 or the use according to claim 36, wherein the cancer is a solid tumour cancer or a metastatic lesion.

38. 38. The method of claim 37 or the use of claim 37, wherein the solid tumor cancer is one or more of pancreatic cancer (e.g. pancreatic adenocarcinoma), breast cancer, colorectal cancer, lung cancer (e.g. small cell or non-small cell lung cancer), skin cancer, ovarian cancer, or liver cancer.

39. 37. The method according to claim 35 or the use according to claim 36, wherein the cancer is a blood cancer.

40. 40. The method of any of claims 35 or 37-39 or the use of any of claims 36-39, further comprising the step of administering a second therapeutic treatment.

41. 41. The method of claim 40 or the use of claim 40, wherein the second therapeutic treatment comprises a therapeutic agent (e.g. a chemotherapeutic agent, a biological agent, a hormonal therapy), radiation, or surgery.

42. 42. The method according to claim 41 or the use according to claim 41, wherein the therapeutic agent is selected from a chemotherapeutic agent or a biological agent.

43. 31. A method of treating an autoimmune or inflammatory disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 11, 13, or 15 to 28, wherein the multispecific antibody is administered in an amount effective to treat the autoimmune or inflammatory disorder.

44. 30. An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 11, 13 or 15 to 28 for use in treating an autoimmune or autoinflammatory disorder.

45. 30. A method of treating an infectious disorder, comprising administering to a subject in need thereof an antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 11 or 14 to 28, wherein the multispecific antibody is administered in an amount effective to treat the infectious disorder.

46. 30. An antibody molecule or a multispecific or multifunctional molecule polypeptide according to any of claims 1 to 11 or 14 to 28 for use in treating an infectious disorder.

Images